


# CORONAVIRUS INFORMATION



## Dr Erica Bickerton

Group Leader

Avian Pathology, Molecular Biology, Molecular Virology, Vaccines, Viral Diseases, Virology

Erica graduated from the University of Surrey with first-class honours in Medical Microbiology in 2006. She then joined The Pirbright Institute and completed her PhD with the University of Warwick, graduating in 2011. Erica won the British Poultry Council Scholarship Award in 2010 for work carried out during her PhD on the tropism of the gammacoronavirus, infectious bronchitis virus (IBV).

Erica became an Institute Fellow in 2016 was promoted to Group Leader of the the Coronavirus group in 2018. Her current research utilises molecular virology, next generation sequencing and reverse genetics to characterise the pathogenicity determinants of IBV. Infectious bronchitis is the most economically important infectious disease affecting chickens in the UK and affects not only the production of meat-type birds but also the quality and production levels of eggs from layer and breeder birds. IBV is prevalent in all types of poultry flocks globally and continues to be responsible for economic losses and welfare problems in chickens.

The aim of Erica's research is to develop rationally attenuated vaccines for the better control of infectious bronchitis virus and other coronaviruses. Erica has strong links to major veterinary pharmaceutical companies, is a member of The Pirbright Institute Animal Welfare & Ethical Review Board (AWERB) and was elected to the Microbiology Society virology division committee in 2014.

### Groups

Coronaviruses

As of 02/22/2020: <https://drive.google.com/file/d/1c5Ea6N4E9v1Pxmd2qEfxwryp-0BitB6B>  
<https://login.filesanywhere.com/fs/v.aspx?v=8c6a67885b606e79b197>

## THE 2020 "WORLDWIDE" OUTBREAK OF THE CORONAVIRUS DID NOT OCCUR UNTIL "AFTER" THE JANUARY 15, 2020 "TRADE DEAL" BETWEEN UNITED STATES OF AMERICA'S NAZI/ZIONIST "CORPORATION" EMPIRE and CHINA

The New York Times

### What's in (and Not in) the U.S.-China Trade Deal

The agreement includes some wins for President Trump, but implementing and enforcing the deal could be difficult.

### US-China trade deal: Five things that aren't in it



Karishma Vaswani  
Asia business correspondent  
@BBCKarishma

© 16 January 2020



Jan. 15, 2020



President Trump, along with China's top trade envoy, Liu He, displaying the signed trade deal on Wednesday. Pete Marovich for The New York Times

17 USC § 107 Limitations on Exclusive Rights – FAIR USE



Preventing and controlling viral diseases

[People](#) [Research groups](#) [Publications](#) [Jobs](#) [Contact us](#)[Our science](#)[Science in society](#)[Partnerships](#)[Facilities and resources](#)[Services](#)[Careers and Studentships](#)[News and events](#)[About us](#)[Home](#) » [Scientists](#) » [Dr Erica Bickerton](#)

## Dr Erica Bickerton

Group Leader

**Avian Pathology, Molecular Biology, Molecular Virology, Vaccines, Viral Diseases, Virology**

Erica graduated from the University of Surrey with first-class honours in Medical Microbiology in 2006. She then joined The Pirbright Institute and completed her PhD with the University of Warwick, graduating in 2011. Erica won the British Poultry Council Scholarship Award in 2010 for work carried out during her PhD on the tropism of the gammacoronavirus, infectious bronchitis virus (IBV).

Erica became an Institute Fellow in 2016 was promoted to Group Leader of the the Coronavirus group in 2018. Her current research utilises molecular virology, next generation sequencing and reverse genetics to characterise the pathogenicity determinants of IBV. Infectious bronchitis is the most economically important infectious disease affecting chickens in the UK and affects not only the production of meat-type birds but also the quality and production levels of eggs from layer and breeder birds. IBV is prevalent in all types of poultry flocks globally and continues to be responsible for economic losses and welfare problems in chickens.

The aim of Erica's research is to develop rationally attenuated vaccines for the better control of infectious bronchitis virus and other coronaviruses. Erica has strong links to major veterinary pharmaceutical companies, is a member of The Pirbright Institute Animal Welfare & Ethical Review Board (AWERB) and was elected to the Microbiology Society virology division committee in 2014.

### Groups

Coronaviruses

[News](#)

[Publications](#)

---

[Pirbright's livestock coronavirus research – your questions answered](#)

[Bill & Melinda Gates Foundation funds development of Pirbright's Livestock Antibody Hub supporting animal and human health](#)

[Pirbright partners with ECO Animal Health to combat poultry diseases](#)

[Pirbright scientists identify mutation hotspots that may inform infectious bronchitis vaccine development](#)

[Engineering vaccines for multiple strains of infectious bronchitis virus](#)

## Contact

---

 [Email](#)

---

The Pirbright Institute, Ash Road, Pirbright, Woking, GU24 0NF

Directions

Email: [enquiries@pirbright.ac.uk](mailto:enquiries@pirbright.ac.uk)

Tel: +44 (0)1483 232441

The Pirbright Institute receives strategic funding from BBSRC UKRI.

[Privacy & Cookies](#) | [Terms & Conditions](#) | [Social Media](#) | [eduroam](#) | [Sitemap](#)

© The Pirbright Institute 2020 | A company limited by guarantee, registered in England no. 559784. The Institute is also a registered charity.

Lightflows Web design Surrey

17 USC § 107 Limitations on Exclusive Rights – FAIR USE

loading



(11) **EP 3 172 319 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:  
**20.11.2019 Bulletin 2019/47**

(51) Int Cl.:  
**C12N 7/04** <sup>(2006.01)</sup> **C07K 14/165** <sup>(2006.01)</sup>  
**A61K 39/00** <sup>(2006.01)</sup> **A61K 39/215** <sup>(2006.01)</sup>

(21) Application number: **15750093.5**

(86) International application number:  
**PCT/GB2015/052124**

(22) Date of filing: **23.07.2015**

(87) International publication number:  
**WO 2016/012793 (28.01.2016 Gazette 2016/04)**

(54) **CORONAVIRUS**

CORONAVIRUS

CORONAVIRUS

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

(30) Priority: **23.07.2014 GB 201413020**

(43) Date of publication of application:  
**31.05.2017 Bulletin 2017/22**

(73) Proprietor: **The Pirbright Institute**  
**Pirbright**  
**Woking**  
**Surrey GU24 0NF (GB)**

(72) Inventors:  
• **BICKERTON, Erica**  
**Woking**  
**Surrey GU24 0NF (GB)**  
• **KEEP, Sarah**  
**Woking**  
**Surrey GU24 0NF (GB)**  
• **BRITTON, Paul**  
**Devon EX16 8NN (GB)**

(74) Representative: **D Young & Co LLP**  
**120 Holborn**  
**London EC1N 2DY (GB)**

(56) References cited:  
**WO-A1-2011/004146 WO-A2-2004/092360**  
**WO-A2-2005/049814**

- **V. D. MENACHERY ET AL: "Attenuation and Restoration of Severe Acute Respiratory Syndrome Coronavirus Mutant Lacking 2'-O-Methyltransferase Activity", JOURNAL OF VIROLOGY, vol. 88, no. 8, 29 January 2014 (2014-01-29), pages 4251-4264, XP055215583, ISSN: 0022-538X, DOI: 10.1128/JVI.03571-13**
- **Anonymous: "EM\_STD:KF377577", , 30 October 2013 (2013-10-30), XP55216202, Retrieved from the Internet:  
URL:[http://ibis/exam/dbfetch.jsp?id=EM\\_STD:K F377577](http://ibis/exam/dbfetch.jsp?id=EM_STD:K F377577) [retrieved on 2015-09-25]**
- **PAUL BRITTON ET AL: "Modification of the avian coronavirus infectious bronchitis virus for vaccine development", BIOENGINEERED, vol. 3, no. 2, 1 March 2012 (2012-03-01), pages 114-119, XP055215793, ISSN: 2165-5979, DOI: 10.4161/bbug.18983**
- **MARIA ARMESTO ET AL: "A Recombinant Avian Infectious Bronchitis Virus Expressing a Heterologous Spike Gene Belonging to the 4/91 Serotype", PLOS ONE, vol. 6, no. 8, 30 August 2011 (2011-08-30), page e24352, XP055215311, DOI: 10.1371/journal.pone.0024352**
- **MARIA ARMESTO ET AL: "The Replicase Gene of Avian Coronavirus Infectious Bronchitis Virus Is a Determinant of Pathogenicity", PLOS ONE, vol. 4, no. 10, 9 October 2009 (2009-10-09), page e7384, XP055215449, DOI: 10.1371/journal.pone.0007384 cited in the application**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 3 172 319 B1**

- CAVANAGH ET AL: "Manipulation of the infectious bronchitis coronavirus genome for vaccine development and analysis of the accessory proteins", VACCINE, ELSEVIER LTD, GB, vol. 25, no. 30, 10 July 2007 (2007-07-10), pages 5558-5562, XP022148593, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2007.02.046
- R. CASAIS ET AL: "Reverse Genetics System for the Avian Coronavirus Infectious Bronchitis Virus", JOURNAL OF VIROLOGY, vol. 75, no. 24, 15 December 2001 (2001-12-15), pages 12359-12369, XP055215746, ISSN: 0022-538X, DOI: 10.1128/JVI.75.24.12359-12369.2001
- YAN-QUAN WEI ET AL: "Development and characterization of a recombinant infectious bronchitis virus expressing the ectodomain region of S1 gene of H120 strain", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 98, no. 4, 1 February 2014 (2014-02-01), pages 1727-1735, XP055132063, ISSN: 0175-7598, DOI: 10.1007/s00253-013-5352-5
- WANG ET AL: "Attenuation of porcine reproductive and respiratory syndrome virus strain MN184 using chimeric construction with vaccine sequence", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 371, no. 2, 31 October 2007 (2007-10-31), pages 418-429, XP022439793, ISSN: 0042-6822, DOI: 10.1016/J.VIROL.2007.09.032

**Description**

## FIELD OF THE INVENTION

5 **[0001]** The present invention relates to an attenuated coronavirus comprising a variant replicase gene, which causes the virus to have reduced pathogenicity. The present invention also relates to the use of such a coronavirus in a vaccine to prevent and/or treat a disease.

## BACKGROUND TO THE INVENTION

10 **[0002]** Avian infectious bronchitis virus (IBV), the aetiological agent of infectious bronchitis (IB), is a highly infectious and contagious pathogen of domestic fowl that replicates primarily in the respiratory tract but also in epithelial cells of the gut, kidney and oviduct. IBV is a member of the Order *Nidovirales*, Family *Coronaviridae*, Subfamily *Coronavirinae* and Genus *Gammacoronavirus*; genetically very similar coronaviruses cause disease in turkeys, guinea fowl and pheasants.

15 **[0003]** Clinical signs of IB include sneezing, tracheal rales, nasal discharge and wheezing. Meat-type birds have reduced weight gain, whilst egg-laying birds lay fewer eggs and produce poor quality eggs. The respiratory infection predisposes chickens to secondary bacterial infections which can be fatal in chicks. The virus can also cause permanent damage to the oviduct, especially in chicks, leading to reduced egg production and quality; and kidney, sometimes leading to kidney disease which can be fatal.

20 **[0004]** IBV has been reported to be responsible for more economic loss to the poultry industry than any other infectious disease. Although live attenuated vaccines and inactivated vaccines are universally used in the control of IBV, the protection gained by use of vaccination can be lost either due to vaccine breakdown or the introduction of a new IBV serotype that is not related to the vaccine used, posing a risk to the poultry industry.

25 **[0005]** Further, there is a need in the industry to develop vaccines which are suitable for use *in ovo*, in order to improve the efficiency and cost-effectiveness of vaccination programmes. A major challenge associated with *in ovo* vaccination is that the virus must be capable of replicating in the presence of maternally-derived antibodies against the virus, without being pathogenic to the embryo. Current IBV vaccines are derived following multiple passage in embryonated eggs, this results in viruses with reduced pathogenicity for chickens, so that they can be used as live attenuated vaccines. However such viruses almost always show an *increased* virulence to embryos and therefore cannot be used for *in ovo* vaccination as they cause reduced hatchability. A 70% reduction in hatchability is seen in some cases.

30 **[0006]** Attenuation following multiple passage in embryonated eggs also suffers from other disadvantages. It is an empirical method, as attenuation of the viruses is random and will differ every time the virus is passaged, so passage of the same virus through a different series of eggs for attenuation purposes will lead to a different set of mutations leading to attenuation. There are also efficacy problems associated with the process: some mutations will affect the replication of the virus and some of the mutations may make the virus too attenuated. Mutations can also occur in the S gene which may also affect immunogenicity so that the desired immune response is affected and the potential vaccine may not protect against the required serotype. In addition there are problems associated with reversion to virulence and stability of vaccines.

35 **[0007]** Menachery, V. D. et al. (2014) *J. Virol.*, vol. 88, no. 8, 4251 - 4264, WO 2005/049814 A2 and WO 2004/092360 already disclosed a coronavirus comprising a mutation in nsp-15 and nsp-16 as well as means and methods of how to arrive at a coronavirus comprising such mutated structural proteins.

40 **[0008]** It is important that new and safer vaccines are developed for the control of IBV. Thus there is a need for IBV vaccines which are not associated with these issues, in particular vaccines which may be used for *in ovo* vaccination.

## SUMMARY OF ASPECTS OF THE INVENTION

45 **[0009]** The present inventors have used a reverse genetics approach in order to rationally attenuate IBV. This approach is much more controllable than random attenuation following multiple passages in embryonated eggs because the position of each mutation is known and its effect on the virus, i.e. the reason for attenuation, can be derived.

50 **[0010]** Using their reverse genetics approach, the present inventors have identified various mutations which cause the virus to have reduced levels of pathogenicity. The levels of pathogenicity may be reduced such that when the virus is administered to an embryonated egg, it is capable of replicating without being pathogenic to the embryo. Such viruses may be suitable for *in ovo* vaccination, which is a significant advantage and has improvement over attenuated IBV vaccines produced following multiple passage in embryonated eggs.

55 **[0011]** Thus in a first aspect, the present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in nsp-14, wherein the variant replicase gene encodes a protein comprising an amino acid mutation of Val to Leu at the position corresponding to position 393 of SEQ ID NO:7.

## EP 3 172 319 B1

**[0012]** The variant replicase gene may further encode a protein comprising one or more amino acid mutations selected from the list of:

5 Pro to Leu at position 85 of SEQ ID NO: 6,  
Leu to lie at position 183 of SEQ ID NO: 8;  
Val to lie at position 209 of SEQ ID NO: 9.

**[0013]** The replicase gene may further encode a protein comprising the amino acid mutation Pro to Leu at position 85 of SEQ ID NO: 6.

10 **[0014]** The replicase gene may encode a protein comprising the amino acid mutations Val to Leu at position 393 of SEQ ID NO: 7; Leu to lie at position 183 of SEQ ID NO: 8; and Val to lie at position 209 of SEQ ID NO: 9.

**[0015]** The replicase gene may encode a protein comprising the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6; Val to Leu at position 393 of SEQ ID NO: 7; Leu to lie at position 183 of SEQ ID NO: 8; and Val to lie at position 209 of SEQ ID NO: 9.

15 **[0016]** The replicase gene may comprise one or more nucleotide substitutions selected from the list of:

20 C to T at nucleotide position 12137;  
G to C at nucleotide position 18114;  
T to A at nucleotide position 19047; and  
G to A at nucleotide position 20139;  
compared to the sequence shown as SEQ ID NO: 1.

**[0017]** The coronavirus may be an infectious bronchitis virus (IBV).

**[0018]** The coronavirus may be IBV M41.

25 **[0019]** The coronavirus may comprise an S protein at least part of which is from an IBV serotype other than M41.

**[0020]** For example, the S1 subunit or the entire S protein may be from an IBV serotype other than M41.

**[0021]** The coronavirus according to the first aspect has reduced pathogenicity compared to a coronavirus expressing a corresponding wild-type replicase, such that when the virus is administered to an embryonated egg, it is capable of replicating without being pathogenic to the embryo.

30 **[0022]** In a second aspect, a variant replicase gene as defined in the claims is provided.

**[0023]** In a third aspect, a protein encoded by a variant coronavirus replicase gene as defined in the claims is provided.

**[0024]** In a fourth aspect, a plasmid comprising a replicase gene as defined in the claims is provided.

**[0025]** In a fifth aspect, a method for making the coronavirus as defined in the claims is provided which comprises the following steps:

- 35 (i) transfecting a plasmid according to the fourth aspect of the invention into a host cell;  
(ii) infecting the host cell with a recombining virus comprising the genome of a coronavirus strain with a replicase gene;  
(iii) allowing homologous recombination to occur between the replicase gene sequences in the plasmid and the corresponding sequences in the recombining virus genome to produce a modified replicase gene; and  
40 (iv) selecting for recombining virus comprising the modified replicase gene.

**[0026]** The recombining virus may be a vaccinia virus.

**[0027]** The method may also include the step:

45 (v) recovering recombinant coronavirus comprising the modified replicase gene from the DNA from the recombining virus from step (iv).

**[0028]** A cell capable of producing a coronavirus according to the first aspect is provided.

**[0029]** In a another aspect, a vaccine comprising a coronavirus as defined in the claims and a pharmaceutically acceptable carrier is provided.

50 **[0030]** Also described herein is a method for treating and/or preventing a disease in a subject which comprises the step of administering a vaccine according to the invention to the subject.

**[0031]** Further aspects of the invention provide:

- the vaccine as defined in the claims for use in preventing a disease in a subject.

55 **[0032]** Also described herein is the use of a coronavirus according to the first aspect in the manufacture of a vaccine for treating and/or preventing a disease in a subject.

**[0033]** The disease may be infectious bronchitis (IB).

**[0034]** The method of administration of the vaccine may be selected from the group consisting of; eye drop adminis-

tration, intranasal administration, drinking water administration, post-hatch injection and *in ovo* injection.

[0035] Vaccination may be by *in ovo* vaccination.

[0036] The present invention also provides a method for producing a vaccine as defined in the claims which comprises the step of infecting a cell as defined in the claims with a coronavirus as defined in the claims.

5

DESCRIPTION OF THE FIGURES

[0037]

10 **Figure 1** - Growth kinetics of M41-R-6 and M41-R-12 compared to M41-CK (M41 EP4) on CK cells

**Figure 2** - Clinical signs, snicking and wheezing, associated with M41-R-6 and M41-R-12 compared to M41-CK (M41 EP4) and Beau-R (Bars show mock, Beau-R, M41-R 6, M41 - R 12, M41-CK EP4 from left to right of each timepoint).

15

**Figure 3** - Ciliary activity of the viruses in tracheal rings isolated from tracheas taken from infected chicks. 100% ciliary activity indicates no effect by the virus; apathogenic, 0% activity indicates complete loss of ciliary activity, complete ciliostasis, indicating the virus is pathogenic (Bars show mock, Beau-R, M41-R 6, M41-R 12, M41-CK EP4 from left to right of each timepoint).

20

**Figure 4** - Clinical signs, snicking, associated with M41R-nsp10rep and M41R-nsp14,15,16rep compared to M41-R-12 and M41-CK (M41 EP5) (Bars show mock, M41-R12; M41 R-nsp10rep; M41 R-nsp14,15,16rep and M41-CK EP5 from left to right of each timepoint).

25

**Figure 5** - Ciliary activity of M41R-nsp10rep and M41R-nsp14,15,16rep compared to M41-R-12 and M41-CK in tracheal rings isolated from tracheas taken from infected chicks (Bars show mock; M41-R12; M41R-nsp10rep; M41R-nsp14,15,16rep and M41-CK EP5 from left to right of each timepoint).

30

**Figure 6** - Clinical signs, snicking, associated with M41R-nsp10, 15rep, M41R-nsp10, 14, 15rep, M41R-nsp10, 14, 16rep, M41 R-nsp10, 15, 16rep and M41-K compared to M41-CK (Bars show mock, M41R-nsp10,15rep1; M41R-nsp10,14,16rep4; M41R-nsp10,15,16rep8; M41R-nsp10,14,15rep10; M41-K6 and M41-CK EP4 from left to right of each timepoint).

35

**Figure 7** - Clinical signs, wheezing, associated with M41R-nsp10, 15rep, M41R-nsp10, 14, 15rep, M41R-nsp10, 14, 16rep, M41 R-nsp1 0, 15, 16rep and M41-K compared to M41-CK (Bars show mock, M41R-nsp10,15rep1; M41R-nsp10,14,16rep4; M41R-nsp10,15,16rep8; M41R-nsp10,14,15rep10; M41-K6 and M41-CK EP4 from left to right of each timepoint).

40

**Figure 8** - Ciliary activity of M41R-nsp1 0, 15rep, M41 R-nsp1 0, 14, 15rep, M41R-nsp10, 14, 16rep, M41R-nsp10, 15, 16rep and M41-K compared to M41-CK in tracheal rings isolated from tracheas taken from infected chicks (Bars show mock, M41R-nsp10,15rep1; M41R-nsp10,14,16rep4; M41R-nsp10,15,16rep8; M41R-nsp10,14,15rep10; M41-K6 and M41-CK EP4 from left to right of each timepoint).

45

**Figure 9** - Growth kinetics of rIBVs compared to M41-CK on CK cells. Fig 9A shows the results for M41-R and M41-K. Fig 9B shows the results for M41-nsp10 rep; M41 R-nsp14, 15, 16 rep; M41 R-nsp1 0, 15 rep; M41 R-nsp10, 15, 16 rep; M41R-nsp10, 14, 15 rep; and M41R-nsp10, 14, 16.

**Figure 10** - Position of amino acid mutations in mutated nsp10, nsp14, nsp15 and nsp16 sequences.

50

**Figure 11** - A) Snicking; B) Respiratory symptoms (wheezing and rales combined) and C) Ciliary activity of rIBV M41R-nsp10,14 rep and rIBV M41R-nsp10,16 rep compared to M41-CK (Bars show mock, M41R-nsp10,14rep; M41R-nsp10,16rep and M41-K from left to right of each timepoint).

55

DETAILED DESCRIPTION

[0038] The present invention provides a coronavirus comprising a variant replicase gene which, when expressed in the coronavirus, causes the virus to have reduced pathogenicity compared to a corresponding coronavirus which comprises the wild-type replicase gene.



CORONAVIRUS

**[0039]** *Gammacoronavirus* is a genus of animal virus belonging to the family *Coronaviridae*. Coronaviruses are enveloped viruses with a positive-sense single-stranded RNA genome and a helical symmetry.

5 **[0040]** The genomic size of coronaviruses ranges from approximately 27 to 32 kilobases, which is the longest size for any known RNA virus.

**[0041]** Coronaviruses primarily infect the upper respiratory or gastrointestinal tract of mammals and birds. Five to six different currently known strains of coronaviruses infect humans. The most publicized human coronavirus, SARS-CoV which causes severe acute respiratory syndrome (SARS), has a unique pathogenesis because it causes both upper and lower respiratory tract infections and can also cause gastroenteritis. Middle East respiratory syndrome coronavirus (MERS-CoV) also causes a lower respiratory tract infection in humans. Coronaviruses are believed to cause a significant percentage of all common colds in human adults.

10 **[0042]** Coronaviruses also cause a range of diseases in livestock animals and domesticated pets, some of which can be serious and are a threat to the farming industry. Economically significant coronaviruses of livestock animals include infectious bronchitis virus (IBV) which mainly causes respiratory disease in chickens and seriously affects the poultry industry worldwide; porcine coronavirus (transmissible gastroenteritis, TGE) and bovine coronavirus, which both result in diarrhoea in young animals. Feline coronavirus has two forms, feline enteric coronavirus is a pathogen of minor clinical significance, but spontaneous mutation of this virus can result in feline infectious peritonitis (FIP), a disease associated with high mortality.

15 **[0043]** There are also two types of canine coronavirus (CCoV), one that causes mild gastrointestinal disease and one that has been found to cause respiratory disease. Mouse hepatitis virus (MHV) is a coronavirus that causes an epidemic murine illness with high mortality, especially among colonies of laboratory mice.

**[0044]** Coronaviruses are divided into four groups, as shown below:

25 Alpha

- Canine coronavirus (CCoV)
- Feline coronavirus (FeCoV)
- Human coronavirus 229E (HCoV-229E)
- 30 • Porcine epidemic diarrhoea virus (PEDV)
- Transmissible gastroenteritis virus (TGEV)
- Human Coronavirus NL63 (NL or New Haven)

35 Beta

- Bovine coronavirus (BCoV)
- Canine respiratory coronavirus (CRCoV) - Common in SE Asia and Micronesia
- Human coronavirus OC43 (HCoV-OC43)
- Mouse hepatitis virus (MHV)
- 40 • Porcine haemagglutinating encephalomyelitis virus (HEV)
- Rat coronavirus (RCV). Rat Coronavirus is quite prevalent in Eastern Australia where, as of March/April 2008, it has been found among native and feral rodent colonies.
- (No common name as of yet) (HCoV-HKU1)
- Severe acute respiratory syndrome coronavirus (SARS-CoV)
- 45 • Middle East respiratory syndrome coronavirus (MERS-CoV)

Gamma

- Infectious bronchitis virus (IBV)
- 50 • Turkey coronavirus (Bluecomb disease virus)
- Pheasant coronavirus
- Guinea fowl coronavirus

55 Delta

- Bulbul coronavirus (BuCoV)
- Thrush coronavirus (ThCoV)
- Munia coronavirus (MuCoV)

- Porcine coronavirus (PorCov) HKU15

**[0045]** The variant replicase gene of the coronavirus of the present invention may be derived from an alphacoronavirus such as TGEV; a betacoronavirus such as MHV; or a gammacoronavirus such as IBV.

**[0046]** As used herein the term "derived from" means that the replicase gene comprises substantially the same nucleotide sequence as the wild-type replicase gene of the relevant coronavirus. For example, the variant replicase gene of the present invention may have up to 80%, 85%, 90%, 95%, 98% or 99% identity with the wild type replicase sequence. The variant coronavirus replicase gene encodes a protein comprising a mutation in one or more of non-structural protein (nsp)-10, nsp-14, nsp-15 or nsp-16 when compared to the wild-type sequence of the non-structural protein.

IBV

**[0047]** Avian infectious bronchitis (IB) is an acute and highly contagious respiratory disease of chickens which causes significant economic losses. The disease is characterized by respiratory signs including gasping, coughing, sneezing, tracheal rales, and nasal discharge. In young chickens, severe respiratory distress may occur. In layers, respiratory distress, nephritis, decrease in egg production, and loss of internal egg quality and egg shell quality are common.

**[0048]** In broilers, coughing and rattling are common clinical signs, rapidly spreading in all the birds of the premises. Morbidity is 100% in non-vaccinated flocks. Mortality varies depending on age, virus strain, and secondary infections but may be up to 60% in non-vaccinated flocks.

**[0049]** The first IBV serotype to be identified was Massachusetts, but in the United States several serotypes, including Arkansas and Delaware, are currently circulating, in addition to the originally identified Massachusetts type.

**[0050]** The IBV strain Beaudette was derived following at least 150 passages in chick embryos. IBV Beaudette is no longer pathogenic for hatched chickens but rapidly kills embryos.

**[0051]** H120 is a commercial live attenuated IBV Massachusetts serotype vaccine strain, attenuated by approximately 120 passages in embryonated chicken eggs. H52 is another Massachusetts vaccine, and represents an earlier and slightly more pathogenic passage virus (passage 52) during the development of H120. Vaccines based on H120 are commonly used.

**[0052]** IB QX is a virulent field isolate of IBV. It is sometimes known as "Chinese QX" as it was originally isolated following outbreaks of disease in the Qingdao region in China in the mid 1990s. Since that time the virus has crept towards Europe. From 2004, severe egg production issues have been identified with a very similar virus in parts of Western Europe, predominantly in the Netherlands, but also reported from Germany, France, Belgium, Denmark and in the UK.

**[0053]** The virus isolated from the Dutch cases was identified by the Dutch Research Institute at Deventer as a new strain that they called D388. The Chinese connection came from further tests which showed that the virus was 99% similar to the Chinese QX viruses. A live attenuated QX-like IBV vaccine strain has now been developed.

**[0054]** IBV is an enveloped virus that replicates in the cell cytoplasm and contains an non-segmented, single-stranded, positive sense RNA genome. IBV has a 27.6 kb RNA genome and like all coronaviruses contains the four structural proteins; spike glycoprotein (S), small membrane protein (E), integral membrane protein (M) and nucleocapsid protein (N) which interacts with the genomic RNA.

**[0055]** The genome is organised in the following manner: 5'UTR - polymerase (replicase) gene - structural protein genes (S-E-M-N) - UTR 3'; where the UTR are untranslated regions (each ~ 500 nucleotides in IBV).

**[0056]** The lipid envelope contains three membrane proteins: S, M and E. The IBV S protein is a type I glycoprotein which oligomerizes in the endoplasmic reticulum and is assembled into homotrimer inserted in the virion membrane via the transmembrane domain and is associated through non-covalent interactions with the M protein. Following incorporation into coronavirus particles, the S protein is responsible for binding to the target cell receptor and fusion of the viral and cellular membranes. The S glycoprotein consists of four domains: a signal sequence that is cleaved during synthesis; the ectodomain, which is present on the outside of the virion particle; the transmembrane region responsible for anchoring the S protein into the lipid bilayer of the virion particle; and the cytoplasmic tail.

**[0057]** All coronaviruses also encode a set of accessory protein genes of unknown function that are not required for replication *in vitro*, but may play a role in pathogenesis. IBV encodes two accessory genes, genes 3 and 5, which both express two accessory proteins 3a, 3b and 5a, 5b, respectively.

**[0058]** The variant replicase gene of the coronavirus of the present invention may be derived from an IBV. For example the IBV may be IBV Beaudette, H120, H52, IB QX, D388 or M41.

**[0059]** The IBV may be IBV M41. M41 is a prototypic Massachusetts serotype that was isolated in the USA in 1941. It is an isolate used in many labs throughout the world as a pathogenic lab stain and can be obtained from ATCC (VR-21™). Attenuated variants are also used by several vaccine producers as IBV vaccines against Massachusetts serotypes causing problems in the field. The present inventors chose to use this strain as they had worked for many years on this virus, and because the sequence of the complete virus genome is available. The M41 isolate, M41-CK, used by the

EP 3 172 319 B1

present inventors was adapted to grow in primary chick kidney (CK) cells and was therefore deemed amenable for recovery as an infectious virus from a cDNA of the complete genome. It is representative of a pathogenic IBV and therefore can be analysed for mutations that cause either loss or reduction in pathogenicity.

**[0060]** The genome sequence of IBV M41-CK is provided as SEQ ID NO: 1.

SEQ ID NO: 1 IBV M41-CK Sequence

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

ACTTAAGATAGATATTAATATATATCTATCACACTAGCCTTGCGCTAGATTTCCAACCTTA  
ACAAAACGGACTTAAATACCTACAGCTGGTCCTCATAGGTGTTCCATTGCAGTGCACCTTT  
AGTGCCCTGGATGGCACCTGGCCACCTGTCAGGTTTTTGTATTTAAAATCTTATTGTTGC  
TGGTATCACTGCTTGTFTTGGCGTGTCTCACTTTATAACATCCGTTGCTTGGGCTACCTAG  
TATCCAGCGTCCTACGGGCGCCGTGGCTGGTTCGAGTGCGAAGAACCCTCTGGTTCATCTA  
GCGGTAGGCGGGTGTGTGGAAGTAGCACTTCAGACGTACCGGTTCTGTTGTGTGAAATAC  
GGGGTCACCTCCCCCACATAACCTCTAAGGGCTTTTGAGCCTAGCGTTGGGCTACGTTCT  
CGCATAAGGTTCGGCTATACGACGTTTGTAGGGGGTAGTGCCAAACAACCCCTGAGGTGAC  
AGGTTCTGGTGGTGTTTAGTGAGCAGACATAACAATAGACAGTGACAACATGGCTTCAAGC  
CTAAACAGGGAGTATCTCCAAACTAAGGGATGTCATTCTTGTATCCAAAGACATTCTT  
GAACAACCTTTGTGACGCTTTGTTTTTCTATAACGTCACACAACCCTAAGGATTACGCTGAT  
GCTTTTGCAGTTAGGCAGAAGTTTGTATCGTAATCTGCAGACTGGGAAACAGTTCAAATTT  
GAAACTGTGTGGTCTCTTCTCTTGAAGGGAGTTGACAAAATAACACCTGGCGTCCCA  
GCAAAAGTCTTAAAAGCCACTTCTAAGTTGGCAGATTTAGAAGACATCTTTGGTGTCTCT

EP 3 172 319 B1

CCCTTTGCAAGAAAATATCGTGAACTTTTGAAGACAGCATGCCAGTGGTCTCTTACTGTA  
 GAAACACTGGATGCTCGTGCACAACTCTTGATGAAATTTTTGACCCTACTGAAATACTT  
 TGGCTTCAGGTGGCAGCAAAAATCCAAGTTTTCGGCTATGGCGATGCGCAGGCTTGTGGA  
 5 GAAGTAACTGCAAAAGTCATGGATGCTTTGGGCTCAAATATGAGTGTCTTTTTCCAGATT  
 TTTAAACAACAAATAGTCAGAATTTTTCAAAAAGCGCTGGCTATTTTTGAGAATGTGAGT  
 GAATTACCACAGCGTATTTGCAGCACTTAAGATGGCTTTTGTCTAAGTGTGCCAAGTCCATT  
 ACTGTTGTGGTTATGGAGAGGACTCTAGTTGTTAGAGAGTTCGCAGGAAGTGTCTTTGCA  
 AGCATTAAATGGTGTCTTTGCAAAAATCTTTGAAGAACTCCCAAATGGTTTCATGGGTGCT  
 10 AAAATTTTCACTACACTTGCCTTCTTTAGGGAGGCTGCAGTGAATAATGTGGATAACATA  
 CCAAATGCACCGAGAGGCACTAAAGGGTTTGAAGTCGTTGGTAATGCCAAAGGTACACAA  
 GTTGTGTGCGTGGCATGCGAAATGACTTAACACTGCTTGACCAAAAAGCTGAAATTCCT  
 GTGGAGTCAGAAGGTTGGTCTGCAATTTTTGGGTGGACATCTTTGCTATGTCTTTAAGAGT  
 GGTGATCGCTTTACGCGGCACCTCTTTGAGAAATTTGCATTGCATGATGTGCATTGT  
 TGTGAGCGTGTGTCTGTCTTTCTGATGGTGTAAACACCGGAGATAAATGAGCTTATT  
 15 CTTGCAGCTAATCTACTCTTCTTTAGTGTGCGCAGAACTTGTGGCAGCCATTAAAAGGGGT  
 GAACCATTAAAGTTTTCTGGGTGATAAATTTGTGTATGCAAAGGATGCAGCAGTTTCTTTT  
 ACATTAGCGAAGGCTGCTACTATTGCAGATGTTTTGAAGCTGTTTCAATCAGCGCGTGTG  
 AAAGTAGAAGATGTTTTGGTCTTCACTTACTGAAAAGTCTTTTGAATTCTGGAGGCTTGCA  
 TATGAAAAGTGCCTAATCTCGAAGAATTTGTTAAGACTTGTTTTTGTAAGGCTCAAATG  
 20 GCGATTGTGATTTTAGCGACAGTGTGGAGAGGGCATTTGGCATCTTGTTCGCAAGTC  
 ATCTATAAAGTAGGTGGTCTTTTTACTAAAGTTGTTGACTTTTGTGAAAATATTGGAAA  
 GGTTTTTGTGCACAGTTGAAAAGAGCTAAGCTCATTGTCACTGAAACCCTCTGTGTTTTG  
 AAAGGAGTTGCACAGCATTTGTTTTCAACTATTGCTGGATGCAATACAGTTTATGTATAAA  
 AGTTTTAAGAAGTGTGCACTTGGTAGAATCCATGGAGACTTGCCTTCTGGAAAGGAGGT  
 25 GTGCACAAAATTAATCAAGAGGGCGATGAAATTTGGTTTGACGCCATTGATAGTATTGAT  
 GTTGAAGATCTGGGTGTGTTCAAGAAAATTTGATTGATTTGATGTTTTGTGATAATGTG  
 AACTTCCAGAGAACCAACCGGTCATATGGTTCAAATCGAGGATGACGGAAAGAAGTAC  
 ATGTTCTTCCGCTTCAAAAAGGATGAGAACATTTATTATACACCAATGTCACAGCTTGGT  
 GCTATTAATGTGGTTTTGCAAAGCAGGCGGTAAAACCTGTCACCTTTGGAGAACTACTGTG  
 30 CAAGAAATACCACCACCTGATGTTGTGTTTATTAAGGTTAGCATTGAGTGTGTGGTGAA  
 CCATGGAATACAATCTTCAAAAAGGCTTATAAGGAGCCCATTGAAGTAGAGACAGACCTC  
 ACAGTTGAACAAATGCTCTCTGTGGTCTATGAGAAAATGTGTGATGATCTCAAGCTGTTT  
 CCGGAGGCTCCAGAACCACCACCTTTGAGAATGTCACACTTGTGATAAGAATGGTAAA  
 GATTTGGATTGCATAAAATCATGCCATCTGATCTATCGTGATTATGAGAGCGATGATGAC  
 35 ATCGAGGAAGAAGATGCAGAAGAATGTGACACGGATTACAGGTGATGCTGAGGAGTGTGAC  
 ACTAATTCAGAAATGTGAAGAAGAAGATGAGGATACTAAAGTGTGGCTCTTATACAAGAC  
 CCGGCAAGTAACAAATATCCTCTGCCTCTTGATGATGATTATAGCGTCTACAATGGATGT  
 APTGTTTATAAGGACGCTCTCGATGTTGTGAATTTACCATCTGGTGAAGAAACCTTTGTT  
 GTCATAACTGCTTTGAAGGGGCTGTTAAAGCTCTTCCGCAAGAAAGTTATTGATGTTCTA  
 40 GGTGACTGGGGTGAAGGCTGTTGATGCGCAAGAACAATGTGTCAACAAGAATCAACTCGG  
 GTCATATCTGAGAAATCAGTTGAGGGTTTTACTGGTAGTTGTGATGCAATGGCTGAACAA  
 GCTATTGTTGAAGAGCAGGAAATAGTACCTGTTGTGTAACAAAGTCAGGATGTAGTTGTT  
 TTTACACCTGCAGACCTAGAAGTTGTTAAAGAAACAGCAGAAGAGGTTGATGAGTTTATT  
 CTCATTTCTGCTGTCCCTAAAGAAGAAGTTGTGTCTCAGGAGAAAGAGGACACAGGTT  
 45 GAGCAAGAGCCTACCTAGTTGTTAAAGCACAAACGTGAGAAGAAGGCTAAAAGTTCAA  
 GTTAAACCAGCTACATGTGAAAACCCAAATTTTTGGAGTACAAAACATGTGTGGGTGAT  
 TTGGCTGTTGTAATTGCCAAAGCATTGGATGAGTTTAAAGAGTTCTGCATTGTAACGCT  
 GCAAATGAGCACATGTCGCATGGTGGTGGCGTTGCAAAGGCAATTGCAGACTTTTTGTGGA  
 CCGGACTTTGTTGAATATTGCGCGGACTATGTTAAGAAACATGGTCCACAGCAAAAACCT  
 50 GTCACACCTTCAATTTGTTAAAGGCATTCAATGTGTGAATAATGTTGTAGGACCTCGCCAT  
 GGAGACAGCAACTTGCCTGAGAAGCTTGTGCTGCTTACAAGAGTGTCTTGTAGGTGGA  
 GTGGTTAACTATGTTGTGCCAGTTCTCTCATCAGGGATTTTTGGTGTAGATTTTAAAATA  
 TCAATAGATGCTATGCGCGAAGCTTTTTAAAGGTTGTGCCATACGCGTCTTTTTATTTTCT  
 CTGAGTCAAGAACACATCGATTATTTTCGATGCAACTTGTAAAGCAGAAGACAATTTATCTT  
 55 ACGGAGGATGGTGTAAATACCGCTCTGTTGTTTTAAAACCTGGTGATTCTTTGGGTCAA  
 TTTGGACAGGTTTTTGAAGAAATAAGGTAGTCTTTTCGGCTGATGATGTTGAGGATAAA  
 GAAATCCTCTTTATACCCACAACCTGACAAGACTATTCTTGAATATTATGGTTTAGATGCG

EP 3 172 319 B1

CAAAAGTATGTAACATATTTGCAAACGCTTGCGCAGAAATGGGATGTTCAATATAGAGAC  
 AATTTTGTATATATAGAGTGGCGTGACGGAAATTTGCTGGATTAGTTCAGCAATAGTTCTC  
 CTTCAAGCTGCTAAAATTAGATTTAAAGGTTTTCTTGCAGAAGCATGGGCTAAACTGTTG  
 5 GGTGGAGATCCTACAGACTTTGTTGCCTGGTGTATGCAAGTTGCAATGCTAAAGTAGGT  
 GATTTTTAGATGCTAATTTGGCTTTTGGCCAATTTAGCAGAACATTTTGACGCAGATTAC  
 ACAAATGCACTTCTTAAGAAGTGTGTGTCGTGCAATTGTGGTGTAAAGAGTTATGAACTT  
 AGGGGTCTTGAAGCCTGTATTCAGCCAGTTCCGAGCACCTAATCTTCTACATTTTAAAACG  
 CAATATTCAAATTGCCCAACCTGTGGTGAAGTAGTACGGATGAAGTAATAGAAGCTTCA  
 10 TTACCGTACTTATTGCTTTTTGCTACTGATGGTCTGCTACAGTTGATTGTGATGAAAAT  
 GCTGTAGGGACTGTTGTTTTTATTGGCTCTACTAATAGTGGCCATTGTTATACACAAGCC  
 GATGGTAAGGCTTTTGACAATCTTGCTAAGGATAGAAAATTTGGAAGGAAGTCGCCTTAC  
 ATTACAGCAATGTATACACGTTTTTCTCTTAGGAGTGAAAATCCCCTACTTGTGTTGAA  
 CATAAGGCTAAAGCTAAAGTAGTAAAAGAAGATGTTTCTAACCTTGCTACTAGTTCT  
 AAAGCCAGTTTGTGACGATCTTACTGACTTTGAAACAGTGGTATGATAGCAACATCTATGAG  
 15 AGTCTTAAAGTGCAGGAGACACCTGATAATCTTGATGAATATGTGTCATTTACGACAAAG  
 GAAGATTCTAAGTTGCCACTGACACTTAAAGTTAGAGGTATCAAATCAGTTGTTGACTTT  
 AGGTCTAAGGATGGTTTTACTTATAAGTTAACACCTGATACTGATGAAAATTCAAAAACA  
 CCAGTCTACTACCCAGTCTTGGATTCTATTAGTCTTAGGGCAATATGGGTTGAAGGCAGT  
 GCTAATTTTTGTTGTTGGGCATCCAAATTATTATAGTAAGTCTCTCCGAATTTCCACGTTT  
 20 TGGGAAAATGCCGAGAGCTTTGTTAAAATGGGTATAAAAATTTGATGGTGTAACTATGGGC  
 CTTTTGGCGTGCAAGACACCTTAATAAACCTAATTTGGAGAGAATTTTTAACATTGCTAAG  
 AAAGCTATTGTTGGATCTAGTGTGTTACTACGCAGTGTGGTAAAATACTAGTTAAAGCA  
 GCTACATACGTTGCCGATAAAGTAGGTGATGGTGTAGTTCGCAATATTACAGATAGAATF  
 AAGGGTCTTTGTGGATTCACACGTGGCCATTTTTGAAAAGAAAATGTCCCTACAATTTCTA  
 25 AAGACACTTGTGTTCTTTTTCTTTTTATTTCTTAAAGGCTAGTGTAAAGAGTTTAGTTTCT  
 AGCTATAAGATTTGTGTTATGTAAGGTGGTGTGTTGCTACCTTACTTATAGTGTGGTTTATA  
 TACACAAGTAATCCAGTAGTGTTTACTGGAATACGTGTGCTAGACTTCCTATTTGAAGGT  
 TCTTTATGTGGTCTTATAATGACTACGGTAAAGATTTCTTTGATGTGTTACGCTATTGT  
 GCAGGTGATTTTACTTGTGCTGTGTGTTTACATGATAGAGATTCACTTCATCTGTACAAA  
 30 CATGCTTATAGCGTAGAACAAATTTATAAGGATGCAGCTTCTGGCATTAACTTTAATTGG  
 AATTGGCTTTAATTTGGTCTTTCTAATATTTATTTGTTAAGCCAGTGGCAGGTTTTGTTATT  
 ATTTGTTATTGTGTTAAGTATTTGGTATTGAGTTCAACTGTGTTGCAAACCTGGTGTAGGT  
 TTTCTAGATTTGGTTTGTAAAAACAGTTTTTACCCATTTTAAATTTATGGGAGCGGGATTT  
 TATTTCTGGCTCTTTTACAAGATATACGTACAAGTGCATCATATATTGFACTGTAAGGAT  
 35 GTAACATGTGAAGTGTGCAAGAGAGTTGCACGCAGCAACAGGCAAGAGGTTAGCGTTGTA  
 GPTGGTGGACGCAAGCAAATAGTGCATGTTTACACTAATTTCTGGCTATAACTTTTGTAAG  
 AGACATAATTTGGTATTGTAGAAATTTGTGATGATTATGGTCACCAAAATACATTTATGTCC  
 CCTGAAGTTGCTGGCGAGCTTTCTGAAAAGCTTAAAGCCCATGTTAAACCTACAGCATAT  
 GCTTACCACGTTGTGTATGAGGCATGCGTGGTTGATGATTTTGTAAATTTAAAATATAAG  
 40 GCTGCAATTCCTGGTAAGGATAATGCATCTTCTGCTGTTAAGTGTTCAGTGTACAGAT  
 TTTTTAAAGAAAGCTGTTTTTCTTAAAGGAGGCATTGAAATGTGAACAAATATCTAATGAT  
 GGTTTTATAGTGTGTAATACACAGAGTGGCATGCACTAGAGGAAGCAAAGAATGCAGCC  
 GTCTATTATGCGCAATATCTGTGTAAGCCAATACTTATACTTGACCAGGCACTTTATGAG  
 CAATTAATAGTAGACCCTGTGTCTAAGAGTGTATAGATAAAGTGTGTAGCATTTTGTCT  
 45 AATATAATATCTGTAGATACTGCAGCTTTAAATTTATAAGGCAGGCACACTTCGTGATGCT  
 CTGCTTTCTAATTAATAAGACGAAGAAGCCGTAGATATGGCTATCTTCTGCCACAATCAT  
 GAAGTGAATACACTGGTGACGGTTTTTACTAATGTGATACCGTCATATGGTATGGACACT  
 GATAAGTTGACACCTCGTGATAGAGGGTTTTTGATAAATGCAGATGCTTCTATTGCTAAT  
 TTAAGAGTCAAAAATGCTCCTCCGGTAGTATGGAAGTTTTCTGATCTTATTAATTTGTCT  
 50 GACAGTTGCCCTTAAATATTTAATTTTACGCTACTGTCAAGTCAGGAGGTCGTTTTCTTTATA  
 ACAAAGTCTGGTGTAAACAAGTTATTTCTTGTATACCCAGAACTGTTGGTAGAGAAA  
 AAGGCAGGTGGTGTATTATAAACACTTTTAAATGGTTTTATGAGTTGTTTTAAATGGCTT  
 TTTGTCTTTTATATACTTTTACAGCATGTTGTTTGGGTTACTACTATATGGAGATGAAT  
 AAAAGTTTTGTTCACCCCATGTATGATGTAAACTCCACACTGCATGTTGAAGGGTTCAAA  
 55 GTTATAGACAAAGGTGTTATTAGAGAGATTGTGTCAGAAGATAATTGTTTTCTAATAAG  
 TTTGTTAATTTTGACGCCTTTTGGGGTAAATCATATGAAAATAATAAAAACGTGCTCAATT  
 GTTACAGTTGTTATAGATGGTGACGGGACAGTAGCTGTTGGTGTCTGGTTTTGTATCA

TGGGTTATGGATGGTGTATGTTTGTGCATATGACACAGACTGATCGTAGACCTTGGTAC  
 ATTCCTACCTGGTTTAAATAGAGAAATTGTTGGTTACACTCAGGATTCGAATTATCACTGAG  
 GGTAGTTTTTATACATCTATAGCATTATTTTTCTGCTAGATGTTTATATTTAACAGCCAGC  
 AATACACCTCAATTGTATTGTTTTAATGGCGACAATGATGCACCTGGAGCCTTACCATTT  
 5 GGTAGTATTATTCCTCATAGAGTATACTTCCAACCTAATGGTGTTAGGCCTTATAGTTCCA  
 CAACAAATACTGCATACACCCTACATAGTGAAGTTTGTTCAGACAGCTATTGTAGAGGT  
 AGTGTATGTGAGTATACTAAACCAGGTTACTGTGTGTCACTAGACTCCCAATGGGTTTTG  
 TTTAATGATGAATACATTAGTAAACCTGGCGTTTTCTGTGGTCTACTGTTAGAGAACTT  
 10 ATGTTTAAATATGGTTAGTACATTCTTTACTGGTGTCAACCTAATATTTATATTCAGCTA  
 GCAACTATGTTTTAATACTAGTTGTTATTGTGTTAATTTTTGCAATGGTTATAAAGTTT  
 CAAGGTGTTTTAAAGCTTATGCGACCATTGTGTTTACAATAATGTTAGTTTGGGTATT  
 AATGCATTTGTTTTGTGTGTACATAGTTATAATAGTGTTTTAGCTGTTATATTATTAGTA  
 CTCTATTGCTATGCATCATTGGTTACAAGTCCGAATACTGCTATAATAATGCATTGTTGG  
 CTTGTTTTTACCTTTGGTTTTAATAGTACCACATGGTTGGCTTGTGCTATCTGGGATT  
 15 ATTCGTTTATATGTACACACCCTGGTTTTCTGGTGTACGGTACTACTAAAAATACTCGT  
 AAGTTGTATGATGGCAACGAGTTTGGTTGGTAATTATGACCTTGCTGCGAAGAGCACTTTT  
 GTTATTCGTGGTACTGAATTTGTTAAGCTTACGAATGAGATAGGTGATAAATTTGAAGCC  
 TATCTTTCTGCGTATGCTAGACTTAAATACTATTCAGGCCTGGTAGTGAGCAAGATTAC  
 TTGCAAGCTTGTCTGTCATGGTTAGCTTATGCTTTGGACCAATATAGAAATAGTGGTGT  
 20 GAGGTTGTTTATACCCCACCGCTTACTCTATTGGTGTTAGTAGACTACACGCTGGTTTT  
 AAAAACTAGTTTCTCCTAGTAGTGCTGTTGAGAAAGTGCATTGTTAGTGTCTCTTATAGA  
 GGCAATAATCTTAATGGACTGTGGCTGGGTGATTCTATTTACTGCCACGCCATGTGTTA  
 GGTAAAGTTTAGTGGTGACCAGTGGGGTGACGTAATAACCTTGCTAATAATCATGAGTTT  
 GAAGTTGTAACCTCAAAATGGTGTACTTTGAATGTGTCAGCAGGCGGCTTAAAGGAGCA  
 25 GTTTTTAATTTTACAACTGCAGTTGCCAATGCTGAAACTCCTAAGTATAAGTTTGTAAA  
 GCTAATTTGTTGATAGTTTTCACTATAGCTTGTCTTATGGTGGTACAGTTATAGGACTT  
 TACCCTGTCACTATGCGTCTAATGGTACTATTAGAGCATCTTCTCCTAGCAGGAGCCTGT  
 GGCTCAGTTGGTTTTAATATAGAAAAGGGTGTAGTTAATTTCTTTTATATGCACCATCTT  
 GAGTTACCTAATGCATTACACACTGGAAGTACCTAATGGGTGAGTTTTTATGGTGGTTAT  
 30 GTAGATGAAGAGTTGCGCAAAGAGTGCCACCAGATAAATCTAGTTACTAACAATATTGTA  
 GCATGGCTCTATGCGCAATTATTAGTGTAAAGAAAGTAGTTTTTCCACAACCTAAATGG  
 TTGGAGAGTACTACTGTTTTCTATTGAAGATTACAATAGGTGGGCTAGTGATAATGGTTTT  
 ACTCCATTTTCCACTAGTACTGCTATTACTAAATTAAGTGCTATAACTGGGGTTGATGTT  
 TGTAACCTCCTTCGCCTATTATGGTAAAAAGTGTCAATGGGGTAGTGATCCCATTTTA  
 35 GGACAATATAATTTTGAAGACGAATTGACACCAGAATCTGTATTTAATCAAGTTGGTGGT  
 GPTAGGTTACAGTCTTCTTTTGTAAAGAAAAGCTACATCTTGGTTTTGGAGTAGATGTGTA  
 TTAGCTTGCTTCTTGTGTTGTGTGCTATTGTCTTATTTACGGCAGTGCCACTTAAG  
 TTTTATGTACATGCAGCTGTATTTTTGTTGATGGCTGTGCTCTTTATTTCTTTACTGTT  
 AAACATGTTATGGCATAACATGGACACTTTCCTATTGCCTACATTGATTACAGTTATTTAT  
 40 TTAAGCCAATGGTATGATCCTGTAGTCTTTGATACTATGGTACCATGGATGTTATTGCCA  
 TTAGTGTGTACACTGCTTTAAGTGTGTACAAGGCTGCTATATGAATTTCTTCAATACT  
 TCTTTGTTAATGCTGTATCAGTTTATGAAGTTAGGTTTTGTTATTTACACCTCTTCAAAC  
 ACTCTTACTGCATATACAGAAGGTAATTTGGGAGTTATCTTTGAGTTGGTTACACTATT  
 45 GTGTTGGCTAATGTTAGTAGTAATTCCTAATTTGGTTTTAATGTTTTTAAAGTGTGCTAAG  
 TGGATTTTATATTATTGCAATGCAACATACTTTAATAAATTATGTGTTAATGGCAGTCATG  
 GTTAATGGCATAGGCTGGCTTTGCACCTGTACTTTGGATTGTATTGGTGGGTTAATAAAA  
 GTTTTTGGTTTAAACCTTAGGTAATAACAATTTTAAAGTTTCAGTAGATCAATATAGGTAT  
 ATGTGTTTTGCATAAGGTAATCCACCTAAAACCTGTGTGGGAGGCTTTTACTACAAATATA  
 50 CTTATACAAGGAATTGGAGGCGATCGTGTGTTGCCATAGCTACAGTGCAATCTAAATTG  
 AGTGATGTAAAGTGTACAACCTGTTGTTTTAATGCAGCTTTTGGACTAAGCTTAATGTTGAA  
 GCAAATTCAAAAATGCATGCTTATCTTGTGAGTTACACAATAAAAATCCTCGCATCTGAT  
 GATGTTGGAGAGTGCATGGATAATTTATTGGGTATGCTTATAACACTATTTTGTATAGAT  
 TCTACTATTGATTTGGGTGAGTATTGTGATGATATACTTAAGAGGTCAACTGTATTACAA  
 55 TCGGTTACTCAAGAGTTTTTCGCACATAACCCTCGTATGCTGAATATGAAAGAGCTAAGAGT  
 ATTTATGAAAAGTTTTTAGCCGATTCTAAAATGGTGGTGTAAACACAGCAAGAGCTTGCT  
 GCATATCGTAAAGCTGCCAATATTGCAAAGTCAGTTTTTGTATAGAGACTTGGCTGTTCAA

EP 3 172 319 B1

AAGAAGTTAGATAGCATGGCAGAACGTGCTATGACAACAATGTATAAAGAGGCGCGTGTA  
 ACTGATAGAAGAGCAAAATTAGTTTTATCATTTACATGCACTACTTTTTTCAATGCTTAAG  
 AAAATAGATTTCTGAGAAGCTTAATGTCTTATTTGACCAGGCCGAATAGTGGTGTGTACCC  
 CTAGCAACTGTTCCAATTTGTTTGTAGTAATAAGCTTACCCTTGTATACCAGACCCAGAG  
 5 ACGTGGGTCAAGTGTGTGGAGGGTGTGCATGTTACATATCAACAGTTGTTTTGGAATATA  
 GACTGTGTTACTGATGCCGATGGCACAGAGTTACACCCCACTTCTACAGGTAGTGGATTG  
 ACTTACTGTATAAGTGGTGATAATATAGCATGGCCTTTAAAGGTTAACTTGACTAGGAAT  
 GGGCATAATAAGGTTGATGTTGCCTTGCAAAATAATGAGCTTATGCCTCACGGTGTAAAG  
 10 ACAAAGGCTTGCGTAGCAGGTGTAGATCAAGCACATTTAGCCGTTGAGTCTAAATGTTAT  
 TATACAAGTATTAGTGGCAGTTTCAAGTTGTAGCTGCTATTACCTCTTCAAATCCTAATCTG  
 AAAGTAGCCTCTTTTTGAATGAGGCAGGTAATCAGATTTATGTAGACTTAGACCCACCA  
 TGTAAATTTGGTATGAAAGTGGTGATAAGGTTGAAGTTGTTTACCTGTATTTTATAAAA  
 AATACGAGGTCTATGTAGAGGTATGGTACTTGGTGCTATATCTAATGTTGTTGTGTTA  
 CAATCTAAAGGTCATGAGACAGGAAGTGGATGCTGTAGGCATTCTCTCACCTTTGTTCT  
 15 TTTGACTAGATCCTGCGGATACATATTTGTAATAATGTGGCAGCAGGTAATCAACCTTTA  
 GGTAAGTGTGTTAAAATGTTGACAGTACATAATGGTAGTGGTTTTGCAATAACATCAAAG  
 CCAAGTCCAACCTCCGGATCAGGATTCTTATGGAGGAGCTTCTGTGTGCTTTTATTGTAGA  
 GCACATATAGCACACCCTGGCGGAGCAGGAAATTTAGATGGACGCTGTCAATTTAAAGGT  
 TCTTTTGTGCAAATACCTACTACGGAGAAAGATCCTGTTGGATTCTGTCTACGTAACAAG  
 20 GTTTTGCACTGTTTGTGAGTGGTGGATTGGTTATGGATGTCAGTGTGATTCACTTAGACAA  
 CCTAAACCTTCTGTTTCAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT  
 GGGTACGGGGTAGCAGTGGGCTCGGCTGATACCCCTAGCTAATGGATGTGACCCCGATG  
 TTTGTAAGCGAGCCTTTGATGTTTGTAAATAAGGAATCAGCCGGTATGTTTTCAAAATTTGA  
 AGCGTAACTGTGCACGATTTCCAAGAAGTACGTGATACTGAAGATGGAATCTTGAGTATTT  
 25 GTGATTTCTATTTTGTGGTTAAACAAACCCTCCTAGTAATTTATGAACATGAGAAAGCTT  
 GTTATGAAGACTTAAAGTCAGAAGTAACAGCTGATCATGATTTCTTTGTGTTCAATAAGA  
 ACATTTATAATATTAGTAGGCAGAGGCTTACTAAGTATACTATGATGGATTTTTGCTATG  
 CTTTTCGGGCACTTTGACCCAAAGGATTGCGAAGTTCTTAAAGAAATACTTGTCACTTATG  
 GTTGTATAGAAGATTATCACCCTAAGTGGTTTGAAGAGAATAAGGATTTGGTACGACCCAA  
 30 TAGAAAACCCTAATATTTATGCCATGTTGGCTAAAATGGGACCTATTGTACGACGTGCTT  
 TATTGAATGCTATTGAGTTCGGAAACCTCATGGTTGAAAAAGGTTATGTTGGTGTATTATTA  
 CACTTGATAACCAAGATCTTAATGGCAAATTTTATGATTTTGGTGTATTTTCAGAAGACAG  
 CGCCTGGTGTGGTGTCCCTGTTTTTGTATACGTATTATTTCTTACATGATGCCCATCATAG  
 CCATGACTGATGCGTTGGCACCTGAGAGGTATTTTTGAATATGATGTGCATAAGGGTTATA  
 35 AATCTTATGATCTCCTCAAGTATGATTATACTGAGGAGAAACAAGATTTGTTTTCAGAAGT  
 ACTTTAAGTATTGGGATCAAGAGTATCACCCCTAACTGTGCGGACTGTAGTGATGACAGGT  
 GTTTTGATACATTTGTGCAAACCTCAACATCTTGTTTTCTACACTTGTACCCGAGACTTCTT  
 TCGGTAATTTGTGTAGAAAGGTTTTTGTGGTGTACCATTATAGCTACTTGTGGCT  
 ATCATTCTAAGGAACTTGGTGTATTATGAATCAAGATAACACCATGTCATTTTCAAAA  
 40 TGGGTTTGGTCAACTCATGCAGTTTGTGGAGATCCTGCCCTTGTAGTGGGACATCCA  
 ATAAATTAGTGGATCTTAGAACGTCTTGTTTTAGTGTGTTGTGCTTTAGCGTCTGGTATTA  
 CTCATCAAACGGTAAAACCAGGTCACCTTAAACAAGGATTTCTACGATTTTGCAGAGAAGG  
 CTGGTATGTTTAAAGGAAGGTTCTTCTATACCACTTAAACATTTCTTCTACCCACAGACTG  
 GTAATGCTGCTATAAACGATTTATGATTATTATCGTTATAACAGGCCTACCATGTTTGATA  
 45 TACGTCAACTTTTATTTTGTTTAGAAGTGACTTCTAAATATTTGAATGTTATGAAGGCG  
 GCTGTATACCAGCAAGCCAAGTTGTAGTTAACAATTTAGATAAGAGTGCAGGTTATCCGT  
 TCAATAAGTTTGGAAAGGCCCTCTCTATTATGAAATGAGTCTAGAGGAGCAGGACCAAC  
 TCTTTGAGAGTACAAAGAAGAACGTCCTGCTACTATAACTCAGATGAATTTAAATATG  
 CCATATCCGCGAAAAATAGAGCGGTACAGTGGCAGGTGTGTCTATCCTTTCTACTATGA  
 50 CTAATAGGCAGTTTTCATCAGAAGATTCTTAAAGTCTATAGTCAACACTAGAAACGCTCCTG  
 TAGTTATTGGAACAACCAAGTTTTATGGCGGTTGGGATAACATGTTGAGAAACCTTATTC  
 AGGGTGTGGAAGACCCGATTCTTATGGGTTGGGATTATCCAAAGTGTGATAGAGCAATGC  
 CTAATTTGTTGCGTATAGCAGCATCTTTAGTACTCGCTCGTAAACACACTAATTGTTGTA  
 CTTGGTCTGAACGCGTTTATAGGTTGTATAATGAATGCGCTCAGGTTTTATCTGAAACTG  
 55 TCTTAGCTACAGGTGGTATATATGTGAAACCTGGTGGTACTAGCAGTGGAGATGCTACTA  
 CTGCTTATGCAAACAGTGTTTTCAACATAATAACAAGCCACATCTGCTAATGTTGCGCGTC  
 TTTTGAAGTGTATAACGCGTATATTGTATATGATGACATTAAGAGCTTGCAGTATGAAT

EP 3 172 319 B1

TGTACCAGCAGGTTTATAGGCGAGTCAATTTTGACCCAGCATTGTTGAAAAGTTTTATT  
 CTTATTTGTGTAAGAATTTCTCATTGATGATCTTGTCTGACGACGGTGTGTTTGTATA  
 ACAACACATFAGCCAAACAAGGCTTTGTAGCAGATATTTCTGGTTTTAGAGAAGTTCTCT  
 5 ACTATCAGAACAATGTTTTATGGCTGATTCTAAATGTTGGGTTGAACCAGATTTAGAAA  
 AAGGCCACATGAATTTTGTTCACAGCACACAATGTTAGTGGAGGTTGATGGTGAGCCTA  
 GATACTTGCCATATCCAGACCCATCACGTATTTTGTGTGCATGTGTTTTTGTAGATGATT  
 TGGATAAGACAGAATCTGTGGCTGTTATGGAGCGTTATATCGCTCTTGCCATAGATGCGT  
 10 ACCACTAGTACATCATGAAAATGAGGAGTACAAGAAGGTATTCCTTTGTGCTTCTTTTCAT  
 ACATCAGAAAACCTCATCAAGAGCTTTCTCAGAATATGCTTATGGACTACTCTTTTGTAA  
 TGGATATAGATAAGGGTAGTAAATTTTGGGAACAGGAGTTCTATGAAAATATGTATAGAG  
 CCCCTACAACATTACAGTCTTGTGGCGTTTGTGTAGTGTGTAATAGTCAAACCTATATTGC  
 GCTGTGGTAATTTGATTCGCAAACCATTTTGTGTTGTAAGTGTGCTATGACCATGTCA  
 TGCACACAGACCACAAAAATGTTTTGTCTATAAATCCTTACATTTGCTCACAGCCAGGTT  
 15 GTGGTGAAGCAGATGTTACTAAATTTGTACCTCGGAGGTATGTCATACTTCTGCGTTTCA  
 ATAAACCAAGTTATCAATAACCGTTAGTATCTAATGTTACAGTGTGTTGGAATTTACAGGG  
 CTAATTTGTGCAGGTAGCGAAAATGTTGATGATTTTAACTCAACTAGCTACTACTAATGGT  
 CTACTGTGGAACCTTATATTTTGGCAAATCGTTGTGTAGATTCGTTGAGACGCTTTGCTG  
 CAGAGACAGTAAAAGCTACAGAAGAATTACATAAAGCAACAATTTGCTAGTGCAGAAGTGA  
 GAGAAGTACTCTCAGATCGTGAATTTGATTCTGTCTTGGGAGCCAGGTAAAACCAGGCCCTC  
 20 CATTGAATAGAAATTTATGTTTTCACTGGCTTTCACTTTACTAGAACTAGTAAAGTTCAGC  
 TCGGTGATTTTACATTTGAAAAAGGTGAAGGTAAGGACGTTGTCTATTATCGAGCGACGT  
 CTACTGCTAAATTTGTCTGTTGGAGACATTTTGTGTTTAACTCACACAATGTTGTTTCTC  
 TTATAGCGCCACGTTGTGTCCTCAGCAAACCTTTTCTAGGTTTGTGAATTTAAGACCTA  
 ATGTGATGGTACCTGCGTGTGTTTGTAAATAACATTTCCATTTGACCATTTTAGTAGGCAAGC  
 25 AGAAGCGTACTACAGTACAAGGCCCTCCTGGCAGTGGTAAATCCCATTTTGTCTATAGGAT  
 TGGCGGCTTACTTTAGTAACGCCCGTGTGCTTTTACTGCATGCTCTCATGCAGCTGTTG  
 ATGCTTTATGTGAAAAGCTTTTAAAGTTTCTTAAAGTAGATGATTGCACCTCGTATAGTAC  
 CTCAAAGGACTACTATCGATTTGCTTCTCTAAGTTTAAAGCTAATGACACAGGCCAAAAGT  
 ACATTTTATAGTACTATTAATGCCTTGCAGAAAGTTAGTTGTGACATTTCTTTTGGTTGACG  
 30 AGGTTAGTATGTTGACCAATACGAATTTGCTTTTATTAATGGTAAGATAAACTATCAAT  
 ATGTTGTGTATGTTAGGTGATCCTGCTCAATTAACGGCGCCTCGTACGTTGCTTAAACGGTT  
 CACTCTCTCCAAAGGATTTATAATGTTGTCACAAAACCTTATGTTTGTGTTAAACCTGACA  
 TTTTCTTGCAAAAGTGTACCGTTGTCTTAAAGAAATTTGTAGTACTGTTTCTACTCTTG  
 TATATGATGGAAAGTTTATTGCAAATAACCCGGAATCACGTCAGTGTTCAGGTTATAG  
 35 TTAATAATGGTAATTTCTGATGTAGGACATGAAAAGTGGCTCAGCCTACAACATAACTCAAT  
 TAGAATTTGTGAAAGATTTTGTCTGTGCAATAAGGAATGGCGGGAAGCAACATTCATTT  
 CACCTTATAATGCTATGAACCAGAGAGCCTACCGTATGCTTGGACTTAAATGTTTACAGACAG  
 TAGACTCGTCTCAAGGTTTCGGAGTATGATTATGTTATCTTTGTGTTACTGCAGATTCGC  
 AGCATGCATGCAATTTAACAGATTTCAATGTAGCGCTTACAAGAGCCAAGCGTGGTATAC  
 40 TAGTTGTGATGCGTFCAGCGTGTGAACTATATTCAGCTCTTAAAGTTTATAGAGCTTGATA  
 GTGTAGCAAGTCTGCAAGGTACAGGCTTGTTTAAAATTTGCAACAAAGAGTTTAGTGGTG  
 TTCACCCAGCTTATGCAGTCAAACTAAGGCTCTTGTGCAACTTATAAAGTTAATGATG  
 AACTTGCTGCATTTGTTAACGTGGAAGCTGGTTTCAGAAAACATATAAACATCTTATTT  
 CTTTGTAGGGTTTAAAGATGAGTGTAAATGTTGAAGGCTGCCACAACATGTTTATAACAC  
 45 GTGATGAGGCTATCCGCAACGTAAGAGGTTGGGTAGGTTTGTGATGTAGAAGCAACACATG  
 CTTGCGGTACTAACATTTGGTACTAACCTGCCTTTCCAAGTAGGTTTCTCTACTGTTGCAG  
 ACTTTGTAGTTACGCTGAGGACTTGTAGATACTTCAATAGGCAATAATTTTGTAGCCTG  
 TGAATTTCTAAAGCACCTCCAGGTGAACAATTTAATCACTTGTAGAGCGTTATTCAAAGTG  
 CTAAACCTTGGCATGTTGTAAGGCCAAGGATTTGTGCAAATGTTAGCGGATAACCTGTGCA  
 50 ACGTTTTAGATTTGTGTAGTGTGTTGTACAGTGGTGTGATGGCCTAGAACTAACCCTTTGC  
 GCTATTTTGTAAAATAGGCAAGGACCAAGTTTGTCTTGGCGTTCTAGAGCAACAACCTT  
 TTAATTTCTCATACTCAGGCTTATGCTTGTGGAAGCATTTGCTTGGGTTTTGATTTTGT  
 ATAATCCACTCTTAGTGGATATTTCAACAGTGGGGTTATTTCTGGTAACCTACAATTTAACC  
 ATGATTTGCATTTGTAATGTGCATGGACACGCACATGTAGCTTCTGCGGATGCTATTATGA  
 55 CGCGTTGTCTGCAATTAATAATGCATTTTGTCAAGATGTCAACTGGGATTTAACCCTACC  
 CTCATATAGCAAATGAGGATGAAGTCAATTTCTAGCTGTAGATATTTACAACGCATGTATC  
 TTAATGCATGTGTTGATGCTCTTAAAGTTAACGTTGTCTATGATATAGGCAACCCTAAAG



EP 3 172 319 B1

GTATAAAAATGTGTTAGACGTGGAGACTTAAATTTTAGATTCTATGATAAGAATCCAATAG  
TACCCAATGTCAAGCAGTTTGGAGTATGACTATAATCAGCACAAAGATAAGTTTGCTGATG  
GTCTTTGTATGTTTTGGAATTTGTAATGTGGATTGTTATCCCCGACAATTCCTTAGTTTGT  
5 GGTACGACACACGAAATTTGAGTGTGTTTAACTACCTGGTTGTAATGGTGGTAGCTTGT  
ATGTTAAACAAGCATGCATTCACACACCTAAATTTGATCGCACTAGCTTTCGTAATTTGA  
AAGCTATGCCATTCCTTTTCTATGACTCATCGCCTTGGGAGACCATTCAATTTGGATGGAG  
TTGCGCAAGACCTTGTGTCATTAGCTACGAAAGATTGTATCACAAAATGCAACATAGGCG  
10 GTGCTGTTTTGTA AAAAGCACGCACAAATGTATGCAGATTTTGTGACTTCTTATAATGCAG  
CTGTTACTGCTGGTTTTACTTTTTGGGTTACTAATAATTTTAACCCATATAATTTGTGGA  
AAAGTTTTTCAGCTCTCCAGTCTATCGACAATATTGCTTATAATATGTATAAGGGTGGTC  
ATTATGATGCTATTGCAGGAGAAATGCCCACTATCGTAACTGGAGATAAAGTTTTTGTTA  
TAGATCAAGGCGTAGAAAAAGCAGTTTTTTTTTAATCAAACAATTCGCTTACATCTGTAG  
CGTTTTGAGCTGTATGCCAAGAGAAATATTCGCACACTGCCAAACAACCGTATTTTGAAG  
15 GTTTTGGGTGTAGATGTGACTAATGGATTTGTAATTTGGGATTACACGAACCAACACCAC  
TATAACCGTAATACTGTTAAGGTATGTGCATATACAGACATAGAACCAAATGGCCTAATAG  
TGCTGTATGATGATAGATATGGTGATTACCAGTCTTTTCTAGCTGCTGATAATGCTGTTT  
TAGTTTTCTACACAGTGTACAAGCGGTATTTCGTATGTAGAAATACCGTCAAACCTGCTTG  
TTCAGAACGGTATTCCGTTAAAAGATGGAGCGAACCTGTATGTTTTATAAGCGTGTAAATG  
20 GTGCGTTTTGTTACGCTACCTAACACATTAACACACACAGGGTTCGCAGTTATGAAACTTTTTG  
AACCTCGTAGTGATGTTGAGCGTGATTTTTCTCGACATGTCTGAGGAGAGTTTTGTAGAAA  
AGTATGGTAAAGAATTAGGTCTACAGCACATACTGTATGGTGAAGTTGATAAGCCCCAAT  
TAGGTGGTTTTACACACTGTTATAGGTATGTGCAGACTTTTACGTGCGAATAAGTTGAACG  
CAAAGTCTGTTACTAATTTCTGATTTCTGATGTGCATGCAAAATTAATTTTGTATTGGCAGACA  
25 ATGGTTCCACAAGCAAGTGTGTACTGTTGTGGATTTGCTGCTTGATGATTTCTTAGAAC  
TTCTTAGGAACATACTGAAAGAGTATGGTACTAATAAGTCTAAAGTTGTAACAGTGTCAA  
TTGATTACCATAGCATAAATTTTATGACTTGGTTTTGAAGATGGCATTATTA AACATGTT  
ATCCACAGCTTCAATCAGCATGGACGTGTGGTTATAATATGCCTGAACTTTATAAAGTTT  
AGAATTGTGTTATGGAACCTTGCACATTCCTAATTAATGTTGTTGGAATAGCGTTGCCAA  
30 GTGGTATTAATGATGAATGTGGCAAAGTATACACAACCTCTGTCAATACCTTTTGGAAAACA  
CAATGTGTGTACCGCATAATATGCGAGTAATGCATTTTGGAGCTGGAAGTGACAAAGGAG  
TGGCTCCAGGTAGTACTGTTTCTTAACAATGGCTCCCAGAAGGGACACTCCTTGTGCGATA  
ATGATATTGTAGACTATGTGTCTGATGCACATGTTTCTGTGCTTTT CAGATTGCAATAAAT  
ATAAGACAGAGCCAAAGTTTATGATCTTGTGATATCTGATATGTATACAGACAATGATTC  
35 AAAGAAAGCATGAAGGCGTGATAGCCAATAATGGCAATGATGACGTTTTTCATATATCTCT  
CAAGTTTTCTTCGTAATAATTTGGCTCTAGGTGGTAGTTTTGCTGTAAAAGTGACAGAGA  
CAAGTTGGCACGAAGTTTTATATGACATTGCACAGGATTTGTGCATGGTGGACAATGTTTT  
GTACAGCAGTGAATGCCTCTTCTTCAGAAGCATTCTTGGTTGGTGTAAATTAATTTGGGTG  
CAAGTGA AAAAGTTAAGGTTAGTGGAAAACCGCTGCACGCAAATTAATATTTTGGAGGA  
40 ATTTGAATTAATTAACAAACCTCTGCTTATAGTATATTTGACGTGCTAAGTTTGATTTGA  
GATTGAAAAGCAACACCAGTTGTTAATTTGAAAACCTGAACAAAAGACAGACTTAGTCTTTA  
ATTTAATTAAGTGTGGTAAGTTACTGGTAAGAGATGTTGGTAAACACCTCTTTTACTAGTG  
ACTCTTTTGTGTGTAATGATGCTGCTTTGTATGACAGTAGTTCTTACGTTTACTAC  
TACCAAAGTGCTTTAGACCACCTAATGGTTGGCATTACACGGGGGTGCTTATGCGGTA  
GTTAATATTTCTAGCGAATCTAATAATGCAGGCTCTTACCTGGGTGATTTGTTGGTACT  
45 ATTCATGGTGGTTCGTGTTGTTAATGCTTCTTCTATAGCTATGACGGCACCGTCAACAGGT  
ATGGCTGGTCTAGCAGTCAGTTTTGTACTGCACACTGTAACCTTTT CAGATACTACAGTG  
TTTTGTTACACATTTGTTATAAATATGATGGGTGTCCTATAACTGGCATGCTTCAAAGAAT  
TTTTTACGTGTTTCTGCTATGAAAATGGCCAGCTTTTCTATAATTTAACAGTTAGTGTA  
GCTAAGTACCTACTTTTTAAATCATTT CAGTGTGTTAATAAATTTAACATCCGTATATTTA  
50 AATGGTGATCTTGTTTACACCTCTAATGAGACCACAGATGTTACATCTGCAGGTGTTTTAT  
TTTTAAAGCTGGTGGACCTATAACTTATAAAGTTATGAGAGAAGTTAAAGCCCTGGCTTAT  
TTTTGTTAATGGTACTGCACAAGATGTTATTTTGTGTGATGGATCACCTAGAGGCTTGTTA  
GCATGCCAGTATAAATACTGGCAATTTTTT CAGATGGCTTTTATCCTTTTATTAATAGTAGT  
TTAGTTAAGCAGAAGTTTATTGTCTATCGTGAAAATAGTGTTAATACTACTTTTACGTTA  
55 CACAATTTCACTTTTCATAATGAGACTGGCGCCAAACCTAATCCTAGTGGTGTTCAGAAT  
ATTCAAACTTACCAAACACAACAGCTCAGAGTGGTTATTAATTTTAAATTTTTCCTTT  
CTGAGTAGTTTTGTTTATAAGGAGTCTAATTTTATGTATGGATCTTATCACCCAAGTTGT

AATTTTACTAGACTAGAACTATTAATAATGGCTTGTGGTTTAAATTCACCTTTCAGTTTCAATT  
 GCTTACGGTCTCTCAAGGTGGTTGCAAGCAATCTGTCTTCTAGTGGTAGAGCAACTTGT  
 TGTTATGCTTATTCATATGGAGGTCCTTCGCTGTGTAAAGGTGTTTATTCAGGTGAGTTA  
 5 GATCTTAATTTTGAATGTGGACTGTTAGTTTATGTTACTAAGAGCGGTGGCTCTCGTATA  
 CAAACAGCCACTGAACCGCCAGTTATAACTCGACACAATTAATAATAATTAATTTAAAT  
 ACTTGTGTTGATTATAATATATATGGCAGAAGTGGCCAAGGTTTATTAATAATGTAACC  
 GACTCAGCTGTTAGTTATAATATCTAGCAGACGCAGGTTTGGCTATTTTAGATACATCT  
 GGTTCCATAGACATCTTTGTTGTACAAGGTGAATATGGTCTTACTTATTATAAGGTTAAC  
 10 CCTTGGCAAGATGTCAACCAGCAGTTTGTAGTTTCTGGTGGTAAATTAGTAGGTATTCTT  
 ACTTCACGTAATGAGACTGGTCTCAGCTTCTTGAGAACCAGTTTACATTAAAATCACT  
 AATGGAACACGTCGTTTTAGACGTTCTATTACTGAAAATGTTGCAAATGCCCCTTATGTT  
 AGTTATGGTAAGTTTTGTATAAAACCTGATGGTTCAATTGCCACAATAGTACCAAAACAA  
 TTGGAACAGTTTGTGGCACCTTACTTAATGTTACTGAAAATGTGCTCATACTAACAGT  
 TTTAATTTAACTGTTACAGATGAGTACATAACAACCGGTATGGATAAAGTCCAAATTAAT  
 15 TGTCTGCAGTATGTTTTGTGGCAATTTCTCTGGATTGTAGAGATTTGTTTTCAACAATATGGG  
 CCTGTTTTGTGACAACATATTGTCTGTAGTAAATAGTATTGGTCAAAAAGAAGATATGGAA  
 CTTTTGAATTTCTATTCTTCTACTAAACCGGCTGGTTTTAATACACCATTTCTTAGTAAT  
 GTTAGCACTGGTGAGTTTAAATATTTCTTCTGTAAACAACCTCCTAGTAGTCTTAGAAGG  
 CGTTCTTTTTATTGAAGACCTTCTATTTACAAGCGTTGAATCTGTTGGATTACCAACAGAT  
 20 GACGCATACAAAAATGCACTGCAGGACCTTTAGGTTTTCTTAAGGACCTTGCCTGTGCT  
 CGTGAATATAATGGTTTGCCTGTGTTGCCTCCCATTATAACAGCAGAAATGCAAATTTTG  
 TATACTAGTTCTCTAGTAGCTTCTATGGCTTTTTGGTGGTATTACTGCAGCTGGTGTATA  
 CCTTTTGCACACAACCTGCAGGCTAGAATTAATCACTTGGGTATTACCCAGTCACTTTTG  
 TTGAAGAATCAAGAAAAAATGCTGCTTCTTTAATAAGGCCATTGGTCTGATGCAGGAA  
 25 GGTTTTAGAAGTACATCTCTAGCATTACAACAAATCAAGATGTTGTTAATAAGCAGAGT  
 GCTATTCTTACTGAGACTATGGCATCACTTAATAAAAAATTTGGTGTATTTCTTCTATG  
 ATTCAGAAATCTACCAGCAACTTGACGCCATACAAGCAAATGCTCAAGTGGATCGTCTT  
 ATAAGTGGTAGATTGTCATCACTTTCTGTTTTAGCATCTGCTAAGCAGGCGGAGCATATT  
 AGAGTGTACACACAGCGTGAGTTAGCTACTCAGAAAAATTAATGAGTGTGTTAAGTACAG  
 30 TCTATTAGGTACTCTTTTTGTGGTAATGGACGACATGTTCTAACCATACCGCAAAATGCA  
 CCTAATGGTATAGTGTTTATACACTTTTCTTATACTCCAGATAGTTTTGTTAATGTTACT  
 GCAATAGTGGGTTTTTGTGTAAAGCCAGCTAATGCTAGTCAAGTATGCAATAGTACCCGCT  
 AATGGTAGGGTATTTTTATACAAGTTAATGGTAGTTACTACATCACAGCACGAGATATG  
 TATATGCCAAGAGCTATTACTGCAGGAGATATAGTTACGCTTACTTCTTGTCAAGCAAAT  
 35 TATGTAAGTGTAAATAAGACCGTCATTACTACATTCGTAGACAATGATGATTTTGATTTT  
 AATGACGAATTGTCAAAATGGTGGAAATGACACTAAGCATGAGCTACCAGACTTTGACAAA  
 TTCAATTACACAGTACCTATACTTGACATTGATAGTAAAATGATCGTATTCAAGGCGTT  
 ATACAGGGTCTTAATGACTCTTTAATAGACCTTGAAAACTTTCAATACTCAAACTTAT  
 ATTAAGTGGCCTTGGTATGTGTGGTTAGCCATAGCTTTTGGCACTATTATCTTCACTTA  
 40 ATACTAGGATGGGTTTTCTTTCATGACTGGATGTTGTGGTGTGTTGTTGGATGCTTTGGC  
 ATTTATGCCCTAATGAGTAAGTGTGGTAAGAAATCTTCTTATTACACGACTTTTGATAAC  
 GATGTGGTAACCTAACAAATACAGACCTAAAAAGTCTGTTAATGATTCAAAGTCCCACGT  
 CCTTCTAATAGTATTAATTTTTCTTTGGTGTAAACTTGTAAGTTGTTTTAGAGAGT  
 TTATTATAGCGCTCCAACAACCTAATACAAGTTTTACTCCAAATTAATCAATAGTAACTTAC  
 45 AGCCTAGACTGACCCTTTGTACAGTCTAGACTAATGTAAACTTAGAAGCAAATTAATGA  
 AACTGGTGAGCAAGTGATTTCAAAAAATCAGTTTCAATTTACAGCATATTTCAAGTGTATT  
 AAACAGAGAAGTATTTGACCCCTTTGACTATTGTTATTACAGAGGAGGTAATTTTTGGGA  
 AATAGAGTCAGCTGAAGATTGTTGAGGTGATGATGAATTTATTGAATAAGTCCGCTAGAGG  
 AAAATGGAAGTTTTCTAACAGCGCTTTATATATTTGTAGGATTTTTAGCACTTTATCTTC  
 50 TAGGTAGAGCACTTCAAGCATTGTACAGGCTGCTGATGCTTGTGTTTTATTTGGTATA  
 CATGGGTAGTAATTCAGGAGCTAAGGGTACAGCCTTTGTATATAAGTATACATATGGTA  
 GAAAACTTAACAATCCGGAATTAGAAGCAGTTATTGTCAACGAGTTTCTAAGAACGGTT  
 GGAATAATAAAAAATCCAGCAAATTTTCAAGATGTCCAACGAGACAAATGTAAGTCTTGGC  
 TTTGAACAGTCAAGTTGAGCTTTTTAAAGAGTATAATTTATTTATAACTGCATTCTTGTG  
 55 TTCTTAACCATAATACTTCAAGTATGGCTATGCAACAAGAAGTAAGTTTATTTATATACTG  
 AAAATGATAGTGTATGGTGTCTTTTGGCCCTTAACATTCAGTGGTGTAAATTTTCTATGT  
 ATATAACCACCAACACAGGAGGTTCTGTGCGACGGATAATACTTACAGTGTGCTGCTGT

CTGTCTTTTGTAGGTTATTTGGATCCAGAGTATTAGACTCTTTAAGCGGTGTAGGTCATGG  
 TGGTCATTTAAACCCAGAATCTAATGCCGTAGGTTCAATACTCCTAACTAATGGTCAACAA  
 TGTAATTTTGTATAGAGAGTGTGCCAATGGTGCTTTCTCCAATTATAAAGAATGGTGTT  
 5 CTTTATTGTGAGGGTCAGTGGCTTGCTAAGTGTGAACCAGACCACTTGCCTAAAGATATA  
 TTTGTTTGTACACCGGATAGACGTAATATCTACCGTATGGTGCAGAAATATACTGGTGAC  
 CAAAGCGGAAATAAGAAACGGTTTGTCTACGTTTGTCTATGCAAAGCAGTCAGTAGATACT  
 GCGGAGCTAGAAAGTGTAGCAACAGGAGGGAGTAGTCTTTACACCTAAATGTGTGTGTGT  
 AGAGAGTATTTAAAAATTATTCTTTAATAGTGCCTCTATTTTAAAGAGCGCATAATAGTATT  
 10 ATTTTGTAGGATATTAATATAAATCCTCTCTGTTTATACTCTCTTTTCAAGAGCTATTA  
 TTTAAAAAACAGTTTTTCCACTCTTTTGTGCCAAAACTATGTTGTTAATGGTGTAAACC  
 TTTCAAGTAGATAATGGAAAAGTCTACTACGAAGGAAAACCAATTTTTTCAGAAAGGTTGT  
 TGTAGGTTGTGGTTGAGTTATAAAAAAGATTAACCTACTACACTTATTTTTATAAG  
 AGGCGTTTTATCTTACAAGCGCTTAATAAATACGGACGATGAAATGGCTGACTAGTTTTG  
 15 TAAGGGCAGTTATTTTATGTTATAAACCCTATTTAATACTCAATTAAGAGTATTAGATA  
 GGTAAATCTTAGATCATGGACCAAAACACATCTTAACGTGTGTTAGGTGCGTGATTTTTGT  
 TTCAATTAGATTTAGTTTATAGGTTGGCGTATACGCCTACTCAATCGCTGGTATGAATAA  
 TAGTAAAGATAATCCTTTTTTGGCGAGCAATAGCAAGAAAAGCGCGAATTTATCTGAGAGA  
 20 AGGATTAGATTTGTGTTTACTTTCTTAACAAAGCAGGACAAGCAGAGTCTTGTCCCAGGCTG  
 TACCTCTCTAGTATTCAGGGGAAAACCTTGTGAGGAACACAAATATAATAATAATCTTTT  
 GTCATGGCAAGCGGTAAGGCAACTGGAAAGACAGATGCCCCAGCTCCAGTCATCAAACCTA  
 GGAGGACCAAAGCCACCTAAAGTTGGTTCTTCTGGAAATGTATCTTGGTTTCAAGCAATA  
 AAAGCCAAGAAGTTAAATTCACCTCCGCTAAGTTTGAAGGTAGCGGTGTTCCCTGATAAT  
 25 GAAAATCTAAAACCAAGTCAGCAGCATGGATATTGGAGACGCCAAGCTAGGTTTAAGCCA  
 GGTAAAGGTGGAAGAAAACAGTCCCAGATGCTTGGTATTTTTACTATACTGGAACAGGA  
 CCAGCCGCTAACCTGAATTTGGGGTGATAGCCAAGATGGTATAGTGTGGGTTGCTGGTAAG  
 GGTGCTGATACTAAATTTAGATCTAATCAGGGTACTCGTGACTCTGACAAGTTTGACCAA  
 TATCCGCTACGGTTTTTCAGACGGAGGACCTGATGGTAATTTCCGTTGGGATTTTATTCTT  
 30 CTGAATCGTGGCAGGAGTGGGAGATCAACAGCAGCTTCATCAGCAGCATCTAGTAGAGCA  
 CCATCACGTGAAGTTTCGCGTGGTTCGAGGAGTGGTTCTGAAGATGATCTTATTGCTCGT  
 GCAGCAAGGATAATTCAGGATCAGCAGAAGAAGGGTTCTCGCATTACAAAGGCTAAGGCT  
 GATGAAATGGCTCACCGCCGGTATTTGCAAGCGCACATTTCCACCTAATTATAAGGTTGAT  
 CAAGTGTTTGGTCCCCGCTACTAAAGGTAAGGAGGGAAATTTTGGTGTGACAAGATGAAT  
 35 GAGGAAGGTATTAAGGATGGGCGCGTTACAGCAATGCTCAACCTAGTTTCCCTAGCAGCCAT  
 GCTTGTCTTTTTCGGAAGTAGAGTGACGCCAGACTTCAACCAGATGGGCTGCACTTGAAA  
 TTTGAATTTACTACTGTGGTCCCACGTGATGATCCGCAGTTTGATAATTTATGTAATAATTT  
 TGTGATCAGTGTGTTGATGGTGTAGGAACACGTCCAAAAGATGATGAACCAAGACCAAAG  
 TCACGCTCAAGTTCAAGACCTGCAACAAGAGGAAATTTCTCCAGCGCCAAGACAGCAGCGC  
 40 CCTAAGAAGGAGAAAAAGCCAAAGAAGCAGGATGATGAAGTGGATAAAGCATTGACCTCA  
 GATGAGGAGAGGAACAATGCACAGCTGGAATTTGATGATGAACCAAGGTAATTAACCTGG  
 GGGGATTCAGCCCTAGGAGAGAATGAACTTTGAGTAAAATTTCAATAGTAAGAGTTAAGGA  
 AGATAGGCATGTAGCTTGATTACCTACATGTCTATCGCCAGGGAAATGTCTAATTTGTCT  
 45 ACTTAGTAGCCTGGAAACGAACGGTAGACCTTAGATTTTAAATTTAGTTTAAATTTTGTCT  
 TTAGTTTAAAGTTAGTTTAGAGTAGGTATAAAGATGCCAGTGCCGGGGCCACGCGGAGTAC  
 GACCGAGGGTACAGCACTAGGACGCCCATTAGGGGAAGAGCTAAATTTTGTGTTAAGTTA  
 AGTTTAAATTTGGCTATGTATAGTTAAAATTTATAGGCTAGTATAGAGTTAGAGCAAAAAAA  
 50 AAAAAAAAAAAAAAAAAAAAAA

REPLICASE

**[0061]** In addition to the structural and accessory genes, two-thirds of a coronavirus genome comprises the replicase gene (at the 5' end of the genome), which is expressed as two polyproteins, pp1a and pp1ab, in which pp1ab is an extension product of pp1a as a result of a -1 ribosomal shift mechanism. The two polyproteins are cleaved by two types of virus-encoded proteinases usually resulting in 16 non-structural proteins (Nsp1-16); IBV lacks Nsp1 thereby encoding Nsp2-16.

**[0062]** Thus Gene 1 in IBV encodes 15 (16 in other coronaviruses) non-structural proteins (nsp2-16), which are

## EP 3 172 319 B1

associated with RNA replication and transcription.

**[0063]** The term 'replicase protein' is used herein to refer to the pp1a and pp1ab polyproteins or individual nsp subunits.

**[0064]** The term 'replicase gene' is used herein to refer to a nucleic acid sequence which encodes for replicase proteins.

**[0065]** A summary of the functions of coronavirus nsp proteins is provided in Table 1.

Table 1

Nsp Protein	Key features
1	Conserved within but not between coronavirus genetic groups; potential regulatory functions in the host cell.
2	Dispensable for MHV and SARS-CoV replication in tissue culture
3	Acidic domain; macro domain with ADRP and poly(ADP-ribose)-binding activities; one or two ZBD-containing papain-like proteases; Y domain
4	Transmembrane domain
5	3C-like main protease, homodimer
6	Transmembrane domain
7	Interacts with nsp8 to form a hexadecamer complex
8	Noncanonical RNA polymerase; interacts with nsp7 to form a hexadecameric complex
9	ssRNA-binding protein, dimer
10	RNA-binding protein, homododecamer, zinc-binding domain, known to interact with nsp14 and nsp16
11	Unknown
12	RNA-dependent RNA polymerase
13	Zinc-binding domain, NTPase, dNTPase, 5'-to-3' RNA and DNA helicase, RNA 5'-triphosphate
14	3'-to 5' exoribonuclease, zinc-binding domain and N7-methyltransferase
15	Uridylate-specific endoribonuclease, homo-hexamers
16	Putative ribose-2'-O-methyltransferase

**[0066]** The variant replicase gene encoded by the coronavirus of the present invention comprises a mutation in the section of sequence encoding nsp-14 as defined in the claims.

**[0067]** Nsp10 has RNA-binding activity and appears to be involved in homo and/or heterotypic interactions within other nsps from the pp1a/pp1ab region. It adopts an  $\alpha/\beta$  fold comprised of five  $\alpha$ -helices, one  $3_{10}$ -helix and three  $\beta$ -strands. Two zinc-binding sites have been identified that are formed by conserved cysteine residues and one histidine residue (Cys-74/Cys-77/His-83/Cys-90; Cys-117/Cys-120/Cys-128/Cys-130). The protein has been confirmed to bind single-stranded and double-stranded RNA and DNA without obvious specificity. Nsp-10 can be cross-linked with nsp-9, suggesting the existing of a complex network of protein-protein interactions involving nsp-7, -8, -9 and -10. In addition, nsp-10 is known to interact with nsp-14 and nsp-16.

**[0068]** Nsp-14 comprises a 3'-to-5' exoribonuclease (ExoN) active domain in the amino-terminal region. SARS-CoV ExoN has been demonstrated to have metal ion-dependent 3'-to-5' exoribonuclease activity that acts on both single-stranded and double-stranded RNA, but not on DNA. Nsp-14 has been shown to have proof-reading activity. This nsp has also been shown to have N7-methyltransferase (MT) activity in the carboxyl-terminal region. Nsp-15 associated NendoU (nidoviral endoribonuclease, specific for U) RNase activity has been reported for a number of coronaviruses, including SARS-CoV, MHV and IBV. The activities were consistently reported to be significantly enhanced by  $Mn^{2+}$  ions and there was little activity in the presence of  $Mg^{2+}$  and  $Ca^{2+}$ . NendoU cleaves at the 3' side of uridylate residues in both single-stranded and double-stranded RNA. The biologically relevant substrate(s) of coronavirus NendoUs remains to be identified.

**[0069]** Nsp-16 has been predicted to mediate ribose-2'-O-methyltransferase (2'-O-MTase) activity and reverse-genetics experiments have shown that the 2'-O-MTase domain is essential for viral RNA synthesis in HCoV-229E and SARS-CoV. The enzyme may be involved in the production of the cap 1 structures of coronavirus RNAs and it may also cooperate with NendoU and ExoN in other RNA processing pathways. 2'-O-MTase might also methylate specific RNAs to protect them from NendoU-mediated cleavage.

EP 3 172 319 B1

[0070] The genomic and protein sequences for nsp-10, -14, -15 and -16 are provided as SEQ ID NO: 2-5 and 6-9, respectively.

SEQ ID NO: 2 (nsp-10 nucleotide sequence - nucleotides 11884-12318 of SEQ ID NO:1)

5  
TCTAAAGGTCATGAGACAGAGGAAGTGGATGCTGTAGGCATCTCTCACTTTGTTCTTTTGCAGTA  
GATCCTGCGGATACATAATTGTAAATATGTGGCAGCAGGTAATCAACCTTTAGGTAACCTGTGTTAAA  
ATGTTGACAGTACATAATGGTAGTGGTTTTGCAATAACATCAAAGCCAAGTCCAACCTCCGGATCAG  
10 GATTCTTATGGAGGAGCTTCTGTGTGTCTTTATTTGTAGAGCACATATAGCACACCTTGGCGGAGCA  
GGAAATTTAGATGGACGCTGTCAATTTAAAGGTTCTTTTGTGCAAATACCTACTACGGAGAAAGAT  
CCTGTTGGATTCTGTCTACGTAACAAGGTTTGCACCTGTTTGTTCAGTGTGGATTGGTTATGGATGT  
CAGTGTGATTCACTTAGACAACCTAAACCTTCTGTTTCTAG

15 SEQ ID NO: 3 (nsp-14 nucleotide sequence - nucleotides 16938-18500 of SEQ ID NO:1)

GGTACAGGCTTGTTTAAAATTTGCAACAAAGAGTTTAGTGGTGTTCACCCAGCTTATGCAGTCACA  
ACTAAGGCTCTTGGCTGCAACTTATAAAGTTAATGATGAACTTGCTGCACTTGTAAACGTGGAAGCT  
20 GGTTCAGAAATAACATATAAACATCTTATTTCTTTGTTAGGGTTTAAGATGAGTGTAAATGTTGAA  
GGCTGCCACAACATGTTTATAACACGTGATGAGGCTATCCGCAACGTAAGAGGTTGGGTAGGTTTT  
GATGTAGAAGCAACACATGCTTGCAGTACTAACATTGGTACTAACCTGCCTTTCCAAGTAGGTTTT  
TCTACTGGTGCAGACTTTGTAGTTACGCCTGAGGGACTTGTAGATACTTCAATAGGCAATAATTTT  
GAGCCTGTGAATFCTAAAGCACCTCCAGGTGAACAATTTAATCACTTGAGAGCGTTATTCAAAAGT  
25 GCTAAACCTTGGCATGTTGTAAGGCCAAGGATTGTGCAAAATGTTAGCGGATAACCTGTGCAACGTT  
TCAGATTGTGTAGTGTGTTGTACAGTGGTGTGATGGCCTAGAACTAACCCTTTGCGCTATTTTGT  
AAAATAGGCAAGGACCAAGTTTGTCTTGCAGTTCTAGAGCAACAACCTTTAATTCATACTCAG  
GCTTATGCTTGTGGAAGCATTGCTTGGGTTTTGATTTTGTATAATCCACTCTTAGTGGATATT  
CAACAGTGGGGTTATTTCTGGTAACCTACAATTTAACCATGATTTGCATTGTAATGTGCATGGACAC  
30 GCACATGTAGCTTCTGCGGATGCTATTATGACGCGTTGTCTTGCATTAATAATGCATTTTGTCAA  
GATGTCAACTGGGATTTAACTTACCCTCATATAGCAAATGAGGATGAAGTCAATTTCTAGCTGTAGA  
TATTTACAACGCATGTATCTTAATGCATGTGTTGATGCTCTTAAAGTTAACGTTGTCTATGATATA  
GGCAACCCTAAAGGTATTTAAATGTGTTAGACGTGGAGACTTAAATTTTAGATTCTATGATAAGAAT  
CCAATAGTACCCAATGTCAAGCAGTTTGTAGTATGACTATAATCAGCACAAAGATAAGTTTGTCTGAT  
35  
GGTCTTTGTATGTTTTGGAATTGTAATGTGGATGTTATCCCGACAATTCCTTACTTTGTAGGTAC  
GACACACGAAATTTGAGTGTGTTAACCTACCTGGTTGTAATGGTGGTAGCTTGTATGTTAAACAAG  
CATGCATTCACACACCTAAATTTGATCGCACTAGCTTTGTAATTTGAAAGCTATGCCATTCCTTT  
40 TTCTATGACTCATCGCCTTGCAGACCAATTCAATTTGGATGGAGTTGCGCAAGACCTTGTGTCATTA  
GCTACGAAAGATTGTATCACAAAATGCAACATAGCGGTTGCTGTTTGTAAAAAGCACGCACAAATG  
TATGCAGATTTTGTGACTTCTTATAATGCAGCTGTTACTGCTGGTTTTACTTTTTGGGTTACTAAT  
AATTTTAAACCATATAATTTGTGGAAAAGTTTTTCAGCTCTCCAG

45 SEQ ID NO: 4 (nsp-15 nucleotide sequence - nucleotides 18501-19514 of SEQ ID NO:1)

50  
55

EP 3 172 319 B1

5 TCTATCGACAATATTGCTTATAAATATGTATAAGGGTGGTCATTATGATGCTATTGCAGGAGAAATG  
CCCCTATCGTAACTGGAGATAAAGTTTTTGTATAGATCAAGGCGTAGAAAAAGCAGTTTTTTTT  
AATCAAACAATTCTGCCTACATCTGTAGCGTTTGAGCTGTATGCGAAGAGAAATATTCGCACACTG  
10 CCAAACAACCGTATTTTGAAAGSTTTGGGTGTAGATGTGACTAATGGATTTGTAATTTGGGATTAC  
ACGAACCAAACACCCTATAACCGTAATACTGTTAAGGTATGTGCATATACAGACATAGAACCAAAT  
GGCCTAATAGTGCTGTATGATGATAGATATGGTGATTACCAGTCTTTTCTAGCTGCTGATAATGCT  
GTTTTAGTTTTCTACACAGTGTACAAGCGGTATTCGTATGTAGAAATACCGTCAAACCTGCTTGTT  
15 CAGAACGGTATTCGGTTAAAAGATGGAGCGAACCTGTATGTTTATAAGCGTGTAAATGGTGCGTTT  
GTTACGCTACCTAACACAATAAACACACAGGGTFCGAAGTTATGAAACTTTTGAACCTCGTAGTGAT  
GTTGAGCGTGATTTTCTCGACATGTCTGAGGAGAGTTTTGTAGAAAAGTATGGTAAAGAATTAGGT  
CTACAGCACATACTGTATGGTGAAGTTGATAAGCCCCAATTAGGTGGTTCCACACTGTTATAGGT  
ATGTGCAGACTTTTACGTGCGAATAAGTTGAACGCAAAGTCTGTTACTAATTCTGATTCTGATGTC  
15 ATGCAAATTAATTTGTATTGGCAGACAATGGTTCCTACAAGCAAGTGTGTACTGTTGTGGATTTG  
CTGCTTGATGATTTCTTAGAACTTCTTAGGAACATACTGAAAGAGTATGGTACTAATAAGTCTAAA  
GTTGTAACAGTGTCAATTGATTACCATAGCATAAATTTTATGACTTGGTTTGAAGATGGCATTATT  
AAAACATGTTATCCACAGCTTCAA

20 SEQ ID NO: 5 (nsp-16 nucleotide sequence - nucleotides 19515-20423 of SEQ ID NO:1)

25 TCAGCATGGACGTGTGGTTATAAATATGCCTGAACTTTATAAAGTTCAGAAATTGTGTTATGGAACCT  
TGCAACATTCCTAATTATGGTGTGGAAATAGCGTTGCCAAGTGGTATTATGATGAATGTGGCAAAG  
TATACACAACCTCTGTCAATACCTTTCGAAAAACAATGTGTGTACCGCATAATATGCGAGTAATG  
30 CATTTTGGAGCTGGAAGTGACAAAGGAGTGGTGCCAGGTAGTACTGTTCTTAAACAATGGCTCCCA  
GAAGGGACACTCCTTGTGCGATAATGATATTGTAGACTATGTGTCTGATGCACATGTTTCTGTGCTT  
TCAGATTGCAATAAATAAAGACAGAGCACAAGTTTGATCTTGTGATATCTGATATGTATACAGAC  
AATGATTCAAAAAGAAAGCATGAAGGCGTGATAGCCAATAATGGCAATGATGACGTTTTTCATATAT  
35 CTCTCAAGTTTTCTTCGTAATAATTTGGCTCTAGGTGGTAGTTTTGCTGTAAAAGTGACAGAGACA  
AGTTGGCACGAAGTTTTATATGACATTGCACAGGATTGTGCATGGTGGACAATGTTTTGTACAGCA  
GTGAATGCCTCTTCTTCAGAAGCATTCTTGATTGGTGTAAATTATTTGGGTGCAAGTGAAAAGGTT  
AAGGTTAGTGGAAAAACGCTGCACGCAAATTATATATTTTGGAGGAATTGTAATTATTTACAAACC  
TCTGCTTATAGTATATTTGACGTTGCTAAGTTTGATTTGAGATTGAAAGCAACGCCAGTTGTTAAT  
40 TTGAAAACCTGAACAAAAGACAGACTTAGTCTTAATTTAATTAAGTGTGGTAAGTTACTGGTAAGA  
GATGTTGGTAACACCTCTTTTACTAGTGACTCTTTTGTGTGTACTATGTAG

45 SEQ ID NO: 6 (nsp-10 amino acid sequence)

50 SKGHETEEVDAVGILSLCSFAVDPADTYCKYVAAGNQPLGNCVKMLTVHNHSGFAITSKPSPTPDQ  
DSYGGASVCLYCRAHIAHPGGAGNLDGRCQFKGSFVQIPPTTEKDPVGFCLRNKVCTVCQCWIGYGC  
QCDSLRLQPKPSVQ

45 SEQ ID NO: 7 (nsp-14 amino acid sequence)

50 GTGLFKICNKEFSGVHPAYAVTTKALAATYKVND<sup>-</sup>ELAALVNVEAGSEITYKHLISLLGFKMSVNVE  
GCHNMFITRDEAIRNVRGWVGF<sup>-</sup>DVEATHACGTNIGTNLFFQVGFSTGADFVVTPEGLVDTSIGNNF  
EPVNSKAPPEQFNHLRALFKSAKPWHVVRPRIVQMLADNLCNVSDCVVFTWCHGLELTTLRYFV  
55 KIGKDQVCSGSRATTFNSHTQAYACWKHCLGFDFVYNPLLV<sup>-</sup>DIQQWGYSGNLQFNHDLHCNVHGH  
AHVASADAIMTRCLA<sup>-</sup>INNAFCQDVNWD<sup>-</sup>LYPHIANEDEVNSSCRYLQRM<sup>-</sup>YLNACVDALKVNVVYDI  
GNPKGIKCVRRGDLNFRFYDKNPIV<sup>-</sup>PNVKQFEYDYNQHKDKFADGLCMFWNCNVDCYPD<sup>-</sup>NSLVCRY  
DTRNLSVFNLPGCNGGSLYVNKHAFHTPKFDRTSFRNLKAMPFFFYDSSPCETIQLDGVAQDLVSL  
ATKDCITKCNIGGAVCKKHAQMYADFVTSYNAAVTAGFTFWVTNNFNPNLWKSFSALQ

55 SEQ ID NO: 8 (nsp-15 amino acid sequence)

SIDNIAYNMYKGGHYDAIAGEMPTIVTGDKVFVIDQGVKAVFFNQITILPTSVAFELYAKRNIRTL  
 PNNRILKGLGVDVTNGFVIWDYTNQTPLYRNTVKVCAYTDIEPNGLIVLYDDRYGDYQSFLAADNA  
 VLVSTQCYKRYSYVEIPSNLLVQNGIPLKDGANLYVYKRVNGAFVTLPNTLNTQGRSYETFEPRSD  
 5 VERDFLDMSEESFVEKYGKELGLQHI LYGEVDKPOLGGLHTVIGMCRLLLRANKLNAKSVTNSDSV  
 MQNYFVLADNGSYKQVCTVVDLLELDDFLELLRNILKEYGTNKSQVVTVSIDYHSINEMTFWEDGII  
 KTCYPQLQ

SEQ ID NO: 9 (nsp-16 amino acid sequence)

10 SAWTCGYNMPELYKVQNCVMEPCNIPNYGVGIALPFGIMMNVAKYTQLCQYLSKTTMCPVPHNMRVM  
 HFGAGSDKGVAPGSTVLKQWLPEGTLLVDNDIVDYVSDAHVSVLSDCNKYKTEHKFDLVIDSMYTD  
 NDSKRKHEGVIANNGNDDVFIYLLSFLRNNLALGGSFAVKVTETSWHEVLYDIAQDCAWWTMFCTA  
 VNASSSEAFVLGVNYLGASEKVKVSGKTLHANYIFWRNCNYLQTSAYSIFDVAKFDLRLKATPVVN  
 15 LKTEQKTDLVFNLIKCGKLLVRDVGNTSFTSDSFVCTM

REDUCED PATHOGENICITY

20 **[0071]** The live, attenuated coronavirus of the present invention comprises a variant replicase gene as defined in the claims which causes the virus to have reduced pathogenicity compared to a coronavirus expressing the corresponding wild-type gene.

**[0072]** The term "attenuated" as used herein, refers to a virus that exhibits said reduced pathogenicity and may be classified as non-virulent. A live, attenuated virus is a weakened replicating virus still capable of stimulating an immune response and producing immunity but not causing the actual illness.

25 **[0073]** The term "pathogenicity" is used herein according to its normal meaning to refer to the potential of the virus to cause disease in a subject. Typically the pathogenicity of a coronavirus is determined by assaying disease associated symptoms, for example sneezing, snicking and reduction in tracheal ciliary activity.

**[0074]** The term "reduced pathogenicity" is used to describe that the level of pathogenicity of a coronavirus is decreased, lessened or diminished compared to a corresponding, wild-type coronavirus.

30 **[0075]** In one embodiment, the coronavirus of the present invention as defined in the claims has a reduced pathogenicity compared to the parental M41-CK virus from which it was derived or a control coronavirus. The control coronavirus may be a coronavirus with a known pathogenicity, for example a coronavirus expressing the wild-type replicase protein.

**[0076]** The pathogenicity of a coronavirus may be assessed utilising methods well-known in the art. Typically, pathogenicity is assessed by assaying clinical symptoms in a subject challenged with the virus, for example a chicken.

35 **[0077]** As an illustration, the chicken may be challenged at 8-24 days old by nasal or ocular inoculation. Clinical symptoms, associated with IBV infection, may be assessed 3-10 days post-infection. Clinical symptoms commonly assessed to determine the pathogenicity of a coronavirus, for example an IBV, include gasping, coughing, sneezing, snicking, depression, ruffled feathers and loss of tracheal ciliary activity.

**[0078]** The variant replicase of the present invention, when expressed in a coronavirus, may cause a reduced level of clinical symptoms compared to a coronavirus expressing a wild-type replicase.

40 **[0079]** For example a coronavirus expressing the variant replicase may cause a number of snicks per bird per minute which is less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20% or less than 10% of the number of snicks caused by a virus expressing the wild type replicase.

**[0080]** A coronavirus expressing a variant replicase according to the present invention may cause wheezing in less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20% or less than 10% of the number of birds in a flock infected with the a virus expressing the wild type replicase.

45 **[0081]** A coronavirus expressing a variant replicase according to the present invention may result in tracheal ciliary activity which is at least 60%, at least 70%, at least 80%, at least 90% or at least 95% of the level of tracheal ciliary activity in uninfected birds.

50 **[0082]** A coronavirus expressing a variant replicase according to the present invention may cause clinical symptoms, as defined in Table 2, at a lower level than a coronavirus expressing the wild type replicase.

Table 2 IBV severity limits based on clinical signs:

5	<ul style="list-style-type: none"> <li>Snicking (sneezing)</li> <li>Nasal exudate</li> <li>Watery eyes</li> <li>Swollen infraorbital sinuses</li> </ul>		<p>IBV specific: Mild (N.B. Respiratory signs become apparent from 2-3 dpi if they are going to occur and can continue for up to 7d).</p>
10	<ul style="list-style-type: none"> <li>Rales (vibration in trachea or bronchi region)</li> <li>Hunched posture / depressed</li> <li>Fluffed up feathers</li> </ul>		<p>Mild, if exceed 2d increase to moderate</p>
15	<ul style="list-style-type: none"> <li>Eating and drinking less</li> <li>Drinking in excess: evident by fluid filled crop or measured water intake</li> </ul>		<p>IBV specific: Mild, if exceed 24h increase to moderate for a max of 2d. If still drinking in excess then kill by schedule 1 method.</p>
20	<ul style="list-style-type: none"> <li>Less active but still evade capture</li> <li>Weight loss</li> <li>Not eating or drinking</li> </ul>		<p>Mild, if exceed 1d increase to moderate.</p>
25	<ul style="list-style-type: none"> <li>Birds sit alone and does not evade capture</li> <li>Severe respiratory distress: e.g. excessive gasping</li> <li>Snicking and / or rales for 7d in total</li> </ul>		<p>Moderate: birds at end point. Kill by schedule 1 method.</p>
30	<ul style="list-style-type: none"> <li>Found dead</li> </ul>		<p>Severe: report to project license holder. Full post-mortem to be performed.</p>

35 **[0083]** The variant replicase of the present invention, when expressed in a coronavirus, may cause the virus to replicate at non-pathogenic levels *in ovo*.

40 **[0084]** While developing vaccines to be administered *in ovo* to chicken embryos, attention must be paid to two points: the effect of maternal antibodies on the vaccines and the effect of the vaccines on the embryo. Maternal antibodies are known to interfere with active immunization. For example, vaccines with mild strains do not induce protective antibody levels when administered to broiler chickens with maternal antibodies as these strains are neutralized by the maternal antibody pool.

45 **[0085]** Thus a viral particle must be sufficiently efficient at replicating and propagating to ensure that it is not neutralized by the maternally-derived antibodies against the virus. Maternally-derived antibodies are a finite pool of effective antibodies, which decrease as the chicken ages, and neutralization of the virus in this manner does not equate to the establishment of long-term immunity for the embryo/chick. In order to develop long-term immunity against the virus, the embryo and hatched chicken must develop an appropriate protective immune response which is distinct to the effect of the maternally-derived antibodies.

**[0086]** To be useful for *in ovo* vaccination, the virus must also not replicate and propagate at a level which causes it to be pathogenic to the embryo.

50 **[0087]** Reduced pathogenicity in terms of the embryo may mean that the coronavirus causes less reduction in hatchability compared to a corresponding, wild-type control coronavirus. Thus the term "without being pathogenic to the embryo" in the context of the present invention may mean "without causing reduced hatchability" when compared to a control coronavirus.

55 **[0088]** A suitable variant replicase may be identified using methods which are known in the art. For example comparative challenge experiments following *in ovo* vaccination of embryos with or without maternally-derived antibodies may be performed (i.e. wherein the layer has or has not been vaccinated against IBV).

**[0089]** If the variant replicase enables the virus to propagate at a level which is too high, the embryo will not hatch or will not be viable following hatching (i.e. the virus is pathogenic to the embryo). A virus which is pathogenic to the embryo may kill the embryo.



**[0090]** If the variant replicase causes a reduction in viral replication and propagation which is too great, the virus will be neutralised by the maternally-derived antibodies. Subsequent challenge of the chick with IBV will therefore result in the development of clinical symptoms (for example wheezing, snicking, loss of ciliary activity) and the onset of disease in the challenged chick; as it will have failed to develop effective immunity against the virus.

5

VARIANT

**[0091]** As used herein, the term 'variant' is synonymous with 'mutant' and refers to a nucleic acid or amino acid sequence which differs in comparison to the corresponding wild-type sequence.

**[0092]** A variant/mutant sequence may arise naturally, or may be created artificially (for example by site-directed mutagenesis). The mutant may have at least 70, 80, 90, 95, 98 or 99% sequence identity with the corresponding portion of the wild type sequence. The mutant may have less than 20, 10, 5, 4, 3, 2 or 1 mutation(s) over the corresponding portion of the wild-type sequence.

**[0093]** The term "wild type" is used to mean a gene or protein having a nucleotide or amino acid sequence which is identical with the native gene or protein respectively (i.e. the viral gene or protein).

**[0094]** Identity comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % identity between two or more sequences. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A.; Devereux et al., 1984, Nucleic Acids Research 12:387). Examples of other software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel *et al.*, 1999 *ibid* - Chapter 18), FASTA (Atschul et al., 1990, J. Mol. Biol., 403-410) and the GENEWORKS suite of comparison tools, ClustalX (see Larkin et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics, 23:2947-2948). Both BLAST and FASTA are available for offline and online searching (see Ausubel *et al.*, 1999 *ibid*, pages 7-58 to 7-60). However, for some applications, it is preferred to use the GCG Bestfit program. A new tool, called BLAST 2 Sequences is also available for comparing protein and nucleotide sequence (see FEMS Microbiol Lett 1999 174(2): 247-50; FEMS Microbiol Lett 1999 177(1): 187-8 and tatiana@ncbi.nlm.nih.gov).

**[0095]** The sequence may have one or more deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent molecule. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the activity is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.

**[0096]** Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

35

ALIPHATIC	Non-polar	G A P
		I L V
	Polar - uncharged	C S T M
		N Q
	Polar - charged	D E
		K R
AROMATIC		H F W Y

40

45

**[0097]** The coronavirus of the present invention comprises a variant replicase gene as defined in the claims which encodes a protein which comprises a mutation compared to SEQ ID NO: 7 which, when expressed in a coronavirus, causes the virus to have reduced pathogenicity compared to a coronavirus expressing the corresponding wild-type replicase.

50

**[0098]** The variant replicase gene encodes a protein which comprises an amino acid mutation in nsp-14.

**[0099]** The variant replicase gene of the coronavirus as defined in the claims of the present invention may encode a protein comprising a mutation as defined in the M41 mod sequences presented in Figure 10.

55

**[0100]** The variant replicase gene of the coronavirus of the present invention may encode a protein which comprises the amino acid mutations:

## EP 3 172 319 B1

Pro to Leu at position 85 of SEQ ID NO: 6,  
Val to Leu at position 393 of SEQ ID NO: 7;  
Leu to lie at position 183 of SEQ ID NO: 8; and  
Val to lie at position 209 of SEQ ID NO: 9.

5

**[0101]** The variant replicase gene of the coronavirus of the present invention may encode a protein which does not comprise a mutation in nsp-2, nsp-3, nsp-6 or nsp-13.

**[0102]** The variant replicase gene of the coronavirus of the present invention may encode a protein which does not comprise a mutation in nsp10 which corresponds to the threonine to isoleucine mutation caused by a mutation at nucleotide position 12,008 in the gene reported by Ammayappan et al. (Arch Virol (2009) 154:495-499).

10

**[0103]** Ammayappan et al (as above) reports the identification of sequence changes responsible for the attenuation of IBV strain Arkansas DPI. The study identified 17 amino acid changes in a variety of IBV proteins following multiple passages, approx. 100, of the virus in embryonated eggs. It was not investigated whether the attenuated virus (Ark DPI 101) is capable of replicating in the presence of maternally-derived antibodies against the virus *in ovo*, without being pathogenic to the embryo. Given that this virus was produced by multiple passage in SPF embryonated eggs, similar methodology for classical IBV vaccines, it is likely that this virus is pathogenic for embryos. The virus may also be sensitive to maternally-derived antibodies if the hens were vaccinated with a similar serotype.

15

**[0104]** The variant replicase gene of the coronavirus of the present invention may encode a protein which comprises any combination of one or more amino acid mutations provided in the list above.

20

**[0105]** The variant replicase gene may encode a protein which comprises the amino acid mutation Pro to Leu at position 85 of SEQ ID NO: 6.

**[0106]** The variant replicase gene encodes a protein which comprises the amino acid mutation Val to Leu at position 393 of SEQ ID NO: 7.

25

**[0107]** The variant replicase gene may encode a protein which comprises the amino acid mutation Leu to Ile at position 183 of SEQ ID NO: 8.

**[0108]** The variant replicase gene may encode a protein which comprises the amino acid mutation Val to Ile at position 209 of SEQ ID NO: 9.

**[0109]** The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6, and Val to Leu at position 393 of SEQ ID NO: 7.

30

**[0110]** The variant replicase gene may further encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6 Leu to Ile at position 183 of SEQ ID NO: 8.

**[0111]** The variant replicase gene may further encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6 and Val to Ile at position 209 of SEQ ID NO: 9.

35

**[0112]** The variant replicase gene may encode a protein which comprises the amino acid mutations Val to Leu at position 393 of SEQ ID NO: 7 and Leu to Ile at position 183 of SEQ ID NO: 8.

**[0113]** The variant replicase gene may encode a protein which comprises the amino acid mutations Val to Leu at position 393 of SEQ ID NO: 7 and Val to Ile at position 209 of SEQ ID NO: 9.

**[0114]** The variant replicase gene may further encode a protein which comprises the amino acid mutations Leu to Ile at position 183 of SEQ ID NO: 8 and Val to Ile at position 209 of SEQ ID NO: 9.

40

**[0115]** The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6, Val to Leu at position 393 of SEQ ID NO: 7 and Leu to Ile at position 183 of SEQ ID NO: 8.

**[0116]** The variant replicase gene may further encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6 Leu to Ile at position 183 of SEQ ID NO: 8 and Val to Ile at position 209 of SEQ ID NO: 9.

45

**[0117]** The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6, Val to Leu at position 393 of SEQ ID NO: 7 and Val to Ile at position 209 of SEQ ID NO: 9.

**[0118]** The variant replicase gene may encode a protein which comprises the amino acid mutations Val to Leu at position 393 of SEQ ID NO: 7, Leu to Ile at position 183 of SEQ ID NO: 8 and Val to Ile at position 209 of SEQ ID NO: 9.

**[0119]** The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6, Val to Leu at position 393 of SEQ ID NO: 7, Leu to Ile at position 183 of SEQ ID NO: 8 and Val to Ile at position 209 of SEQ ID NO: 9.

50

**[0120]** The variant replicase gene may also be defined at the nucleotide level.

**[0121]** For example the nucleotide sequence of the variant replicase gene of the coronavirus of the present invention may comprise one or more nucleotide substitutions within the regions selected from the list of: 11884-12318, 16938-18500, 18501-19514 and 19515-20423 of SEQ ID NO:1.

55

**[0122]** For example the nucleotide sequence of the variant replicase gene of the coronavirus of the present invention may comprise one or more nucleotide substitutions selected from the list of:

C to T at nucleotide position 12137;

## EP 3 172 319 B1

G to C at nucleotide position 18114;  
T to A at nucleotide position 19047; and  
G to A at nucleotide position 20139;

5 compared to the sequence shown as SEQ ID NO: 1.

**[0123]** As used herein, the term "substitution" is synonymous with the term mutation and means that the nucleotide at the identified position differs to that of the wild-type nucleotide sequence.

**[0124]** The nucleotide sequence may comprise any combination of the nucleotide substitutions selected from the list of:

10 C to T at nucleotide position 12137;  
G to C at nucleotide position 18114;  
T to A at nucleotide position 19047; and  
G to A at nucleotide position 20139;

15 compared to the sequence shown as SEQ ID NO: 1.

**[0125]** The nucleotide sequence may comprise the substitution C12137T.

**[0126]** The nucleotide sequence may comprise substitution G18114C.

**[0127]** The nucleotide sequence may comprise the substitution T19047A.

**[0128]** The nucleotide sequence may comprise the substitution G20139A.

20 **[0129]** The nucleotide sequence may comprise the substitutions C12137T and G18114C.

**[0130]** The nucleotide sequence may comprise the substitutions C12137T and T19047A.

**[0131]** The nucleotide sequence may comprise the substitutions C12137T and G20139A.

**[0132]** The nucleotide sequence may comprise the substitutions G18114C and T19047A.

**[0133]** The nucleotide sequence may comprise the substitutions G18114C and G20139A.

25 **[0134]** The nucleotide sequence may comprise the substitutions T19047A and G20139A.

**[0135]** The nucleotide sequence may comprise the substitutions C12137T, G18114C and T19047A.

**[0136]** The nucleotide sequence may comprise the substitutions C12137T, T19047A and G20139A.

**[0137]** The nucleotide sequence may comprise the substitutions C12137T, G18114C and G20139A.

**[0138]** The nucleotide sequence may comprise the substitutions G18114C, T19047A and G20139A.

30 **[0139]** The nucleotide sequence may comprise the substitutions C12137T, G18114C, T19047A and G20139A.

**[0140]** The nucleotide sequence may not comprise a substitution which corresponds to the C12008T substitution reported by Ammayappan *et al.* (as above).

**[0141]** The nucleotide sequence may be natural, synthetic or recombinant. It may be double or single stranded, it may be DNA or RNA or combinations thereof. It may, for example, be cDNA, PCR product, genomic sequence or mRNA.

35 **[0142]** The nucleotide sequence may be codon optimised for production in the host/host cell of choice.

**[0143]** It may be isolated, or as part of a plasmid, virus or host cell.

### PLASMID

40 **[0144]** A plasmid is an extra-chromosomal DNA molecule separate from the chromosomal DNA which is capable of replicating independently of the chromosomal DNA. They are usually circular and double-stranded.

**[0145]** Plasmids, or vectors (as they are sometimes known), may be used to express a protein in a host cell. For example a bacterial host cell may be transfected with a plasmid capable of encoding a particular protein, in order to express that protein. The term also includes yeast artificial chromosomes and bacterial artificial chromosomes which are capable of accommodating longer portions of DNA.

45 **[0146]** The plasmid of the present invention comprises a nucleotide sequence capable of encoding a defined region of the replicase protein. It may also comprise one or more additional coronavirus nucleotide sequence(s), or nucleotide sequence(s) capable of encoding one or more other coronavirus proteins such as the S gene and/or gene 3.

50 **[0147]** The plasmid may also comprise a resistance marker, such as the guanine xanthine phosphoribosyltransferase gene (gpt) from *Escherichia coli*, which confers resistance to mycophenolic acid (MPA) in the presence of xanthine and hypoxanthine and is controlled by the vaccinia virus P7.5 early/late promoter.

### RECOMBINANT VACCINIA VIRUS

55 **[0148]** The present invention also relates to a recombinant vaccinia virus (rVV) comprising a variant replicase gene as defined herein.

**[0149]** The recombinant vaccinia virus (rVV) may be made using a vaccinia-virus based reverse genetics system.

**[0150]** In this respect, also provided is a method for making a viral particle by:

- (i) transfecting a plasmid as described in the previous section into a host cell;  
(ii) infecting the host cell with a recombining virus comprising the genome of a coronavirus strain with a replicase gene;  
(iii) allowing homologous recombination to occur between the replicase gene sequences in the plasmid and the corresponding sequences in the recombining virus genome to produce a modified replicase gene;  
(iv) selecting for recombining virus comprising the modified replicase gene.

**[0151]** The term 'modified replicase gene' refers to a replicase gene which comprises a variant replicase gene as defined in the claims.

**[0152]** Specifically, the term refers to a gene which is derived from a wild-type replicase gene but comprises a nucleotide sequence which causes it to encode a variant replicase protein as defined herein.

**[0153]** The recombination may involve all or part of the replicase gene. For example the recombination may involve a nucleotide sequence encoding for any combination of nsp-10, nsp-14, nsp-15 and/or nsp-16. The recombination may involve a nucleotide sequence which encodes for an amino acid mutation or comprises a nucleotide substitution as defined above.

**[0154]** The genome of the coronavirus strain may lack the part of the replicase protein corresponding to the part provided by the plasmid, so that a modified protein is formed through insertion of the nucleotide sequence provided by the plasmid.

**[0155]** The recombining virus is one suitable to allow homologous recombination between its genome and the plasmid. The vaccinia virus is particularly suitable as homologous recombination is routinely used to insert and delete sequences for the vaccinia virus genome.

**[0156]** The above method optionally includes the step:

(v) recovery of recombinant coronavirus comprising the modified replicase gene from the DNA from the recombining virus from step (iv).

**[0157]** Methods for recovering recombinant coronavirus, such as recombinant IBV, are known in the art (See Britton et al (2005) see page 24; and WO2011004146).

**[0158]** For example, the DNA from the recombining virus from step (iv) may be inserted into a plasmid and used to transfect cells which express cytoplasmic T7 RNA polymerase. The cells may, for example be pre-infected with a fowlpox virus expressing T7 RNA polymerase. Recombinant coronavirus may then be isolated, for example, from the growth medium.

**[0159]** When the plasmid is inserted into the vaccinia virus genome, an unstable intermediate is formed. Recombinants comprising the plasmid may be selected for e.g. using a resistance marker on the plasmid.

**[0160]** Positive recombinants may then be verified to contain the modified replicase gene by, for example, PCR and sequencing.

**[0161]** Large stocks of the recombining virus including the modified replicase gene (e.g. recombinant vaccinia virus, (rVV) may be grown up and the DNA extracted in order to carry out step (v)).

**[0162]** Suitable reverse genetics systems are known in the art (Casais et al (2001) J. Virol 75:12359-12369; Casais et al (2003) J. Virol. 77:9084-9089; Britton et al (2005) J. Virological Methods 123:203-211; Armesto et al (2008) Methods in Molecular Biology 454:255-273).

#### CELL

**[0163]** The coronavirus may be used to infect a cell.

**[0164]** Coronavirus particles may be harvested, for example from the supernatant, by methods known in the art, and optionally purified.

**[0165]** The cell may be used to produce the coronavirus particle.

**[0166]** Thus the present invention also provides a method for producing a coronavirus as defined in the claims which comprises the following steps:

- (i) infection of a cell with a coronavirus according to the invention;  
(ii) allowing the virus to replicate in the cell; and  
(iii) harvesting the progeny virus.

**[0167]** Also provided is a cell capable of producing a coronavirus using a reverse genetics system. For example, the cell may comprise a recombining virus genome comprising a nucleotide sequence capable of encoding the replicase gene of the present invention.

**[0168]** The cell may be able to produce recombinant recombining virus (e.g. vaccinia virus) containing the replicase gene.

**[0169]** Alternatively the cell may be capable of producing recombinant coronavirus by a reverse genetics system. The

cell may express or be induced to express T7 polymerase in order to rescue the recombinant viral particle.

#### VACCINE

5 **[0170]** The coronavirus may be used to produce a vaccine. The vaccine may be a live attenuated form of the coronavirus of the present invention and may further comprise a pharmaceutically acceptable carrier. As defined herein, "pharmaceutically acceptable carriers" suitable for use in the invention are well known to those of skill in the art. Such carriers include, without limitation, water, saline, buffered saline, phosphate buffer, alcohol/aqueous solutions, emulsions or suspensions. Other conventionally employed diluents and excipients may be added in accordance with conventional techniques. Such carriers can include ethanol, polyols, and suitable mixtures thereof, vegetable oils, and injectable organic esters. Buffers and pH adjusting agents may also be employed. Buffers include, without limitation, salts prepared from an organic acid or base. Representative buffers include, without limitation, organic acid salts, such as salts of citric acid, e.g., citrates, ascorbic acid, gluconic acid, histidine-Hel, carbonic acid, tartaric acid, succinic acid, acetic acid, or phthalic acid, Tris, trimethanmine hydrochloride, or phosphate buffers. Parenteral carriers can include sodium chloride solution, Ringer's dextrose, dextrose, trehalose, sucrose, and sodium chloride, lactated Ringer's or fixed oils. Intravenous carriers can include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose and the like. Preservatives and other additives such as, for example, antimicrobials, antioxidants, chelating agents (e.g., EDTA), inert gases and the like may also be provided in the pharmaceutical carriers. The present invention is not limited by the selection of the carrier. The preparation of these pharmaceutically acceptable compositions, from the above-described components, having appropriate pH isotonicity, stability and other conventional characteristics is within the skill of the art. See, e.g., texts such as Remington: The Science and Practice of Pharmacy, 20th ed, Lippincott Williams & Wilkins, publ., 2000; and The Handbook of Pharmaceutical Excipients, 4.sup.th edit., eds. R. C. Rowe et al, APhA Publications, 2003.

15 **[0171]** The vaccine as defined in the claims is to be administered in a "therapeutically effective amount", which refers to an amount of an active ingredient, e.g., an agent according to the invention, sufficient to effect beneficial or desired results when administered to a subject or patient. An effective amount can be administered in one or more administrations, applications or dosages. A therapeutically effective amount of a composition may be readily determined by one of ordinary skill in the art. A "therapeutically effective amount" is one that produces an objectively measured change in one or more parameters associated Infectious Bronchitis condition sufficient to effect beneficial or desired results .An effective amount can be administered in one or more administrations. An effective amount of drug, compound, or pharmaceutical composition is an amount sufficient to reduce the incidence of Infectious Bronchitis. As used herein, the term "therapeutic" encompasses the full spectrum of treatments for a disease, condition or disorder. A "therapeutic" agent of the invention may act in a manner that is prophylactic or preventive, including those that incorporate procedures designed to target animals that can be identified as being at risk (pharmacogenetics); or in a manner that is ameliorative or curative in nature; or may act to slow the rate or extent of the progression of at least one symptom of a disease or disorder being treated.

25 **[0172]** The present invention also relates to a method for producing such a vaccine which comprises the step of infecting cells, for example Vero cells, with a viral particle comprising a replicase protein as defined in connection with the first aspect of the invention.

40

#### VACCINATION METHOD

**[0173]** The coronavirus of the present invention may be used to treat and/or prevent a disease.

45 **[0174]** To "treat" means to administer the vaccine to a subject having an existing disease in order to lessen, reduce or improve at least one symptom associated with the disease and/or to slow down, reduce or block the progression of the disease.

**[0175]** To "prevent" means to administer the vaccine to a subject who has not yet contracted the disease and/or who is not showing any symptoms of the disease to prevent or impair the cause of the disease (e.g. infection) or to reduce or prevent development of at least one symptom associated with the disease.

50 **[0176]** The disease may be any disease caused by a coronavirus, such as a respiratory disease and and/or gastroenteritis in humans and hepatitis, gastroenteritis, encephalitis, or a respiratory disease in other animals.

**[0177]** The disease may be infectious bronchitis (IB); Porcine epidemic diarrhoea; Transmissible gastroenteritis; Mouse hepatitis virus; Porcine haemagglutinating encephalomyelitis; Severe acute respiratory syndrome (SARS); or Bluecomb disease.

55 **[0178]** The disease may be infectious bronchitis.

**[0179]** The vaccine may be administered to hatched chicks or chickens, for example by eye drop or intranasal administration. Although accurate, these methods can be expensive e.g. for large broiler flocks. Alternatives include spray inoculation of administration to drinking water but it can be difficult to ensure uniform vaccine application using such

methods.

**[0180]** The vaccine may be provided in a form suitable for its administration, such as an eye-dropper for intra-ocular use.

**[0181]** The vaccine may be administered by *in ovo* inoculation, for example by injection of embryonated eggs. *In ovo* vaccination has the advantage that it provides an early stage resistance to the disease. It also facilitates the administration of a uniform dose per subject, unlike spray inoculation and administration via drinking water.

**[0182]** The vaccine may be administered to any suitable compartment of the egg, including allantoic fluid, yolk sac, amnion, air cell or embryo. It may be administered below the shell (aircell) membrane and chorioallantoic membrane.

**[0183]** Usually the vaccine is injected into embryonated eggs during late stages of embryonic development, generally during the final quarter of the incubation period, such as 3-4 days prior to hatch. In chickens, the vaccine may be administered between day 15-19 of the 21-day incubation period, for example at day 17 or 18.

**[0184]** The process can be automated using a robotic injection process, such as those described in WO 2004/078203.

**[0185]** The vaccine may be administered together with one or more other vaccines, for example, vaccines for other diseases, such as Newcastle disease virus (NDV). The present disclosure also provides a vaccine composition comprising a vaccine disclosed herein together with one or more other vaccine(s). Also provided is a kit comprising a vaccine described herein together with one or more other vaccine(s) for separate, sequential or simultaneous administration.

**[0186]** The vaccine or vaccine composition of the invention may be used to treat a human, animal or avian subject. For example, the subject may be a chick, chicken or mouse (such as a laboratory mouse, e.g. transgenic mouse).

**[0187]** Typically, a physician or veterinarian will determine the actual dosage which will be most suitable for an individual subject or group of subjects and it will vary with the age, weight and response of the particular subject(s).

**[0188]** The composition may optionally comprise a pharmaceutically acceptable carrier, diluent, excipient or adjuvant. The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as (or in addition to) the carrier, excipient or diluent, any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s), and other carrier agents that may aid or increase the delivery or immunogenicity of the virus.

**[0189]** The invention will now be further described by way of Examples, which are meant to serve to assist one of ordinary skill in the art in carrying out the invention.

## EXAMPLES

### EXAMPLE 1 - Generation of an IBV reverse genetics system based on M41-CK

**[0190]** A M41-CK full-length cDNA was produced by replacement of the Beaudette cDNA in the Vaccinia virus reverse genetics system previously described in WO2011/004146 with synthetic cDNA derived from the M41 consensus sequence.

**[0191]** The IBV cDNA within recombinant Vaccinia virus (rVV) rVV-BeauR-Rep-M41 structure described in Armesto, Cavanagh and Britton (2009). PLoS ONE 4(10): e7384. doi:10.1371/journal.pone.0007384, which consisted of the replicase derived from IBV Beaudette strain and the structural and accessory genes and 3' UTR from IBV M41-CK, was further modified by replacement of the Beaudette 5' UTR-Nsp2-Nsp3 sequence with the corresponding sequence from IBV M41-CK. The resulting IBV cDNA consisted of 5' UTR-Nsp2-Nsp3 from M41, Nsp4-Nsp16 from Beaudette and the structural and accessory genes and 3' UTR from M41. This cDNA was further modified by the deletion of the Beaudette Nsp4-Nsp16 sequence. The resulting cDNA, lacking Nsp4-16, was modified in four further steps in which the deleted Nsps were sequentially replaced with the corresponding sequences from M41-CK, the replacement cDNAs represented M41-CK Nsp4-8, Nsp9-12, Nsp12-14 and finally Nsp15-16. Each replacement cDNA contained approx. 500 nucleotides at the 5' end corresponding to the 3' most M41 sequence previously inserted and approx. 500 nucleotides at the 3' end corresponding to the M41 S gene sequence. This allowed insertion of the M41 cDNA sequence by homologous recombination and sequential addition of contiguous M41 replicase gene sequence. The synthetic cDNAs containing the M41-derived Nsp sequences were added by homologous recombination utilising the inventor's previous described transient dominant selection (TDS) system (see WO2011/004146). The M41-derived cDNAs containing sequence corresponding to the M41 Nsps-10, -14, -15 and -16 contained the modified amino acids at positions 85, 393, 183 and 209, respectively, as indicated in Figure 10.

**[0192]** A full-length cDNA representing the genome of M41-CK was generated in Vaccinia virus representing the synthetic sequences. Two rIBVs, M41-R-6 and M41-R-12, were rescued and shown to grow in a similar manner as M41-CK (Fig. 1).

### EXAMPLE 2 - Determining the pathogenicity of rescued M41 viruses

**[0193]** The viruses rescued in Example 1 were used to infect 8-day-old specific pathogen free (SPF) chicks by ocular and nasal inoculation to test them for pathogenicity, as observed by clinical signs on a daily basis 3-7 days post-infection

and for ciliary activity days 4 and 6 post-infection. Loss of ciliary activity is a well-established method for determining the pathogenicity of IBV. The two M41-R viruses were found to be apathogenic when compared to M41-CK though they did show some clinical signs in comparison to uninfected control chicks (Fig. 2) and some but inconsistent loss in ciliary activity (Fig. 3).

**[0194]** Thus, the M41-R molecular clones of M41-CK were not pathogenic when compared to the parental virus M41-CK.

**[0195]** The inventors identified several nucleotide differences in the M41-R compared to the M41-CK sequences. The majority of these were synonymous mutations, as the nucleotide change did not affect the amino acid sequence of the protein associated with the sequence. However, four non-synonymous mutations were identified in the IBV replicase gene specific to Nsp-10, Nsp-14, Nsp-15 and Nsp-16 components of the replicase gene, these mutations resulted in amino acid changes (Table 3).

*Table 3. Non-Synonymous mutations identified in the Nsps of M41-R full-length genome*

Region of Replicase	Nucleotide position	Nucleotide Mutation	Amino Acid Change
Nsp10	12137	C→T	Pro→Leu
Nsp14	18114	G→C	Val→Leu
Nsp15	19047	T→A	Leu→Ile
Nsp16	20139	G→A	Val→Ile

#### EXAMPLE 3 - Repair of M41-R rIBVs

**[0196]** In order to determine whether the identified mutations were responsible for the loss of pathogenicity associated with M41-R, the Nsp10 mutation was repaired and the mutations in Nsp-14, -15 & -16 were repaired and shown to grow in a similar manner as M41-CK (Fig 9). The inventors thus generated the rIBVs, M41R-nsp10rep and M41 R-nsp14, 15, 16rep, using synthetic cDNAs containing the correct nucleotides utilising the inventor's previous described (TDS) system (see WO2011/004146).

**[0197]** The rIBVs were assessed for pathogenicity in chicks as described previously. Both rIBVs showed increased pathogenicity when compared to M41-R but not to the level observed with M41-CK (Figs 4 and 5). M41R-nsp14, 15, 16rep gave more clinical signs and more reduction in ciliary activity than M41R-nsp10rep, overall these results indicated that the changes associated with the four Nsps appear to affect pathogenicity.

**[0198]** To determine the roles of the Nsps in pathogenicity the full-length cDNA corresponding to M41R-nsp10rep was used to repair the mutations in Nsps14, 15 & 16 using a synthetic cDNA containing the correct nucleotides utilising the TDS system.

**[0199]** The following rIBVs were produced:-

- M41R-nsp10, 15rep - M41-R with the mutations in Nsp-10 and Nsp-15 repaired
- M41R-nsp10, 14, 15rep - M41-R with mutations in Nsp-10, -14 and -15 repaired
- M41R-nsp10, 14, 16rep - M41-R with mutations in Nsp-10, -14 and -16 repaired
- M41R-nsp10, 15, 16rep - M41-R with mutations in Nsp-10, -15 and -16 repaired
- M41-K - All four mutations, Nsp-10,-14,-15 & -16 repaired in M41-R

**[0200]** The rIBVs were shown to grow in a similar manner as M41-CK (Fig 9) and assessed for pathogenicity as described previously. M41-K (in which all four mutations had been repaired) resulted in clinical signs and 100% loss of ciliary activity (complete ciliostasis) by 4 days post-infection (Fig. 6, 7 & 8). The other rIBVs demonstrated varying levels of pathogenicity, apart from M41R-nsp10, 15, 16rep, which was essentially apathogenic. These results confirmed that repair of all four Nsps restored pathogenicity to M41-R; again supporting the previous evidence that the mutations described in the four Nsps are implicated in attenuating M41-CK.

**[0201]** The inventors also generated rIBV M41R-nsp 10, 14 rep (nsp 10 and 14 are repaired, nsp 15 and 16 contain mutations) and rIBV M41R-nsp 10, 16 rep (nsp 10 and 16 are repaired, nsp 14 and 15 contain mutations) and assessed the pathogenicity of these viruses.

**[0202]** rIBV M41R-nsp 10, 14 rep less pathogenic than M41-K but caused around 50% ciliostasis on days 4-6 post-infection. rIBV M41R-nsp 10, 16 rep was almost apathogenic and caused no ciliostasis (see Figure 11a-c).

**[0203]** Thus the genome associated with M41-R is a potential backbone genome for a rationally attenuated IBV.

EP 3 172 319 B1

EXAMPLE 4 - Vaccination/Challenge Study with M41-R

[0204] Candidate vaccine viruses were tested in studies in which fertilized chicken eggs were vaccinated *in ovo* at 18 days embryonation and in which the hatchability of the inoculated eggs was determined. The clinical health of the chickens was investigated and the chickens were challenged at 21 days of age with a virulent IB M41 challenge virus at  $10^{3.65}$  EID<sub>50</sub> per dose.

[0205] Clinical signs were investigated after challenge protection by the vaccine and a ciliostasis test was performed at 5 days after challenge to investigate the effect of the challenge viruses on movement of the cilia and protection by the vaccine against ciliostasis (inhibition of cilia movement).

*In ovo vaccination in commercial broiler eggs*

[0206] The design of the experiment is given in Table 4 and the clinical results are given in Table 5. Hatchability of the eggs inoculated with IB M41-R was good and chickens were healthy. IB M41-R protected against clinical signs after challenge in the broilers (placebo: 19/19 affected, IB M41-R: 3/18 affected and 1 dead). The results of the ciliostasis test are given in Table 6. IB M41-R generated protection against ciliostasis.

Table 4 - Design of a hatchability, safety, efficacy study in commercial eggs

Treatment	Treatment Description	EID <sub>50</sub> <sup>1</sup> per dose	Route of Admin	Day(s) of Admin	Day(s) of Challenge <sup>2</sup>	End of Study	Nr. of eggs per treatment
T01	None	NA	NA	NA	NA	NA	30
T02	IB M41-R	10 <sup>4</sup>	In ovo	18 days embryonation	At 21 days of age, 20 chickens per group	At 26 days of age	30
NTX	Saline	NA	In ovo				30

<sup>1</sup> Dose volume 0.1 ml, NA, not applicable.  
<sup>2</sup>  $10^{3.65}$  EID<sub>50</sub> per dose.

Table 5 - Hatch percentages and clinical data before and after challenge in commercial chickens, for design see Table 1.

Treatment	Hatch/total	Vital/total	Before challenge		After challenge	
			Deaths/total	Symptoms/total	Deaths/total	Symptoms/total
None	28/30	Euthanized directly after hatch for blood collection				
IB M41-R	28/30	28/28	1/20	0/19	1/19	3/18 <sup>1,7</sup>
Saline	29/30	29/29	1/20	0/19	0/19	19/19 <sup>1,2,3,4,5,6,7</sup>

<sup>1</sup> Disturbed respiratory system  
<sup>2</sup> Whizzing  
<sup>3</sup> Change of voice  
<sup>4</sup> Breathing difficult  
<sup>5</sup> Swollen intra-orbital sinuses  
<sup>6</sup> Uneven growth  
<sup>7</sup> Weak

Table 6 - Results of the ciliostasis test after challenge, for design see Table 1.

Treatment	Protected/total	Percentage protection
Saline	0/19	0%
IB M41R	5/18	28%



## EP 3 172 319 B1

### *In ovo vaccination in specific pathogen-free (SPF) eggs*

[0207] The design of the study in SPF eggs is given in Table 7 and is similar with the design of the studies with commercial broilers, but the vaccination dose for IB M41-R was higher, ( $10^5$  EID<sub>50</sub> per dose).

[0208] The results (Table 8) show that the hatch percentage for IB M41-R hatch was low, and 19 of 40 hatched and the chicks were weak. Eight chicks died. The remaining 11 chickens were challenged and 11 of the chicks hatched from the eggs which had been inoculated with saline were challenged.

[0209] In the ciliostasis test after challenge it appeared that all chickens vaccinated *in ovo* with IB M41-R were protected, whereas none of the controls was protected, see Table 9.

Table 7. Design of a hatchability, safety, efficacy study in SPF eggs

Treatment	Treatment Description	EID <sub>50</sub> <sup>1</sup> per dose	Route of Admin	Day of Admin	Days of Challenge <sup>2</sup>	End of Study	Nr. of eggs per treatment
T01	IB M41-R	10 <sup>5</sup>	In ovo	18 days embryonation	At 21 days of age	At 26 days of age	40
T04	Saline	NA	In ovo				40
NTX	NA	NA	NA		NA		10

<sup>1</sup> Dose volume 0.1 ml, NA, not applicable.  
<sup>2</sup> Challenge dose 10<sup>3.3</sup> EID<sub>50</sub> in 0.2 ml.

Table 8. Hatch percentages and clinical data before and after challenge in SPF chickens, for design see Table 7.

Treatment	Hatch/total	Vital/total	Before challenge		After challenge	
			Deaths/total	Symptoms/total	Deaths/total	Symptoms/total
IB M41-R	19/40	11/40	8/40	weak	0	0
Saline	30/40	30/40	0	-	0	0
NA	9/10	9/10	0	-	-	-

Table 9. Results of the ciliostasis test after challenge, for design see Table 7.

Treatment	Protected/total	Percentage protection
Saline	0/11	0%
IB M41R	11/11	100%

[0210] In conclusion, IB M41-R was safe in commercial eggs, generated protection against clinical signs and to an extent against ciliostasis.

[0211] In SPF eggs vaccinated with IB M41 R a relatively low number of chickens hatched. This may be due to the  $10^5$  EID<sub>50</sub> per egg of IB M41-R used. This was 10-fold higher than the dose used in earlier studies in which there was a higher level of hatchability. The lower hatch percentages may also be caused by a particularly high susceptibility of the batch of SPF eggs for viruses, as in other studies the level of embryo mortality was also higher that had previously been observed.

[0212] After challenge all surviving chickens after hatch were completely protected against ciliostasis. It is concluded that IB M41-R has great potential as vaccine to be administered *in ovo*.

### Claims

1. A live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in nsp-14, wherein the variant replicase gene encodes a protein comprising an amino acid mutation of Val to Leu at

## EP 3 172 319 B1

the position corresponding to position 393 of SEQ ID NO: 7.

2. The coronavirus according to claim 1 further comprising a mutation in one or more of nsp-10 corresponding to SEQ ID NO: 6, nsp-15 corresponding to SEQ ID NO: 8 and nsp-16 corresponding to SEQ ID NO: 9.
3. The coronavirus according to claim 2 wherein the variant replicase gene encodes a protein comprising one or more amino acid mutations selected from: an amino acid mutation of Pro to Leu at the position corresponding to position 85 of SEQ ID NO: 6, an amino acid mutation of Leu to Ile at the position corresponding to position 183 of SEQ ID NO: 8 and an amino acid mutation of Val to Ile at the position corresponding to position 209 of SEQ ID NO: 9.
4. The coronavirus according to any preceding claim, wherein the replicase gene encodes a protein comprising the amino acid mutations: Pro to Leu at the position corresponding to position 85 of SEQ ID NO: 6; Val to Leu at the position corresponding to position 393 of SEQ ID NO: 7; Leu to Ile at the position corresponding to position 183 of SEQ ID NO: 8; and Val to Ile at the position corresponding to position 209 of SEQ ID NO: 9.
5. The coronavirus according to any preceding claim which is an infectious bronchitis virus (IBV), preferably IBV M41.
6. The coronavirus according to claim 5, which comprises an S protein at least part of which is from an IBV serotype other than M41, preferably wherein the S1 subunit is from an IBV serotype other than M41 or wherein the S protein is from an IBV serotype other than M41.
7. A variant replicase gene as defined in any of claims 1 to 4.
8. A protein encoded by a variant coronavirus replicase gene according to claim 7.
9. A plasmid comprising a replicase gene according to claim 7.
10. A method for making the coronavirus according to any of claims 1 to 6 which comprises the following steps:
  - (i) transfecting a plasmid according to claim 9 into a host cell;
  - (ii) infecting the host cell with a recombining virus comprising the genome of a coronavirus strain with a replicase gene, preferably wherein the recombining virus is a vaccinia virus;
  - (iii) allowing homologous recombination to occur between the replicase gene sequences in the plasmid and the corresponding sequences in the recombining virus genome to produce a modified replicase gene; and
  - (iv) selecting for recombining virus comprising the modified replicase gene; optionally further comprising the step of
  - (v) recovering recombinant coronavirus comprising the modified replicase gene from the DNA from the recombining virus from step (iv).
11. A vaccine comprising a coronavirus according to any of claims 1 to 6 and a pharmaceutically acceptable carrier.
12. The vaccine according to claim 11 for use in preventing a disease in a subject, preferably wherein the disease is infectious bronchitis (IB), most preferably wherein the vaccination is *in ovo* vaccination.
13. The vaccine for use according to claim 12 wherein the vaccine is administered by; eye drop administration, intranasal administration, drinking water administration, post-hatch injection or *in ovo* injection.
14. A method for producing a vaccine according to claim 11, which comprises the step of infecting a host cell with a coronavirus according to any of claims 1 to 6.

### Patentansprüche

1. Lebendes, abgeschwächtes Coronavirus, umfassend eine Polyproteine codierende Replikase-Genvariante, die eine Mutation in nsp-14 umfasst, wobei die Replikase-Genvariante ein Protein codiert, das eine Aminosäuremutation von Val zu Leu an der Position 393 von SEQ ID NO: 7 entsprechenden Position umfasst.
2. Coronavirus nach Anspruch 1, ferner umfassend eine Mutation in einer oder mehreren von nsp-10 gemäß SEQ ID

## EP 3 172 319 B1

NO: 6, nsp-15 gemäß SEQ ID NO: 8 und nsp-16 gemäß SEQ ID NO: 9.

- 5 3. Coronavirus nach Anspruch 2, wobei die Replikase-Genvariante ein Protein codiert, das eine oder mehrere Aminosäuremutationen ausgewählt aus einer Aminosäuremutation von Pro zu Leu an der Position 85 von SEQ ID NO: 6 entsprechenden Position, einer Aminosäuremutation von Leu zu Ile an der Position 183 von SEQ ID NO: 8 entsprechenden Position und einer Aminosäuremutation von Val zu Ile an der Position 209 von SEQ ID NO: 9 entsprechenden Position umfasst.
- 10 4. Coronavirus nach einem vorhergehenden Anspruch, wobei das Replikase-Gen ein Protein codiert, das die folgenden Aminosäuremutationen umfasst: Pro zu Leu an der Position 85 von SEQ ID NO: 6 entsprechenden Position; Val zu Leu an der Position 393 von SEQ ID NO: 7 entsprechenden Position; Leu zu Ile an der Position 183 von SEQ ID NO: 8 entsprechenden Position; und Val zu Ile an der Position 209 von SEQ ID NO: 9 entsprechenden Position.
- 15 5. Coronavirus nach einem vorhergehenden Anspruch, bei dem es sich um ein IBV (Infectious Bronchitis Virus), vorzugsweise IBV M41 handelt.
- 20 6. Coronavirus nach Anspruch 5, das ein S-Protein umfasst, das wenigstens zum Teil von einem anderen IBV-Serotyp als M41 stammt, vorzugsweise wobei die S1-Untereinheit von einem anderen IBV-Serotyp als M41 stammt oder wobei das S-Protein von einem anderen IBV-Serotyp als M41 stammt.
- 25 7. Replikase-Genvariante gemäß einem der Ansprüche 1 bis 4.
8. Protein, codiert durch eine Coronavirus-Replikase-Genvariante nach Anspruch 7.
- 30 9. Plasmid, umfassend ein Replikase-Gen nach Anspruch 7.
- 35 10. Verfahren zur Herstellung des Coronavirus nach einem der Ansprüche 1 bis 6, das die folgenden Schritte umfasst:
  - (i) Transfizieren eines Plasmids nach Anspruch 9 in eine Wirtszelle;
  - (ii) Infizieren der Wirtszelle mit einem rekombinierenden Virus, das das Genom eines Coronavirusstamms mit einem Replikase-Gen umfasst, vorzugsweise wobei es sich bei dem rekombinierenden Virus um ein Vaccinivirus handelt;
  - (iii) Stattfindenlassen einer homologen Rekombination zwischen den Replikase-Gensequenzen im Plasmid und den entsprechenden Sequenzen im Genom des rekombinierenden Virus, so dass ein modifiziertes Replikase-Gen erzeugt wird; und
  - (iv) Selektionieren auf rekombinierendes Virus, das das modifizierte Replikase-Gen umfasst; gegebenenfalls ferner umfassend den Schritt
  - (v) Gewinnen von rekombinantem Coronavirus, das das modifizierte Replikase-Gen umfasst, aus der DNA vom rekombinierenden Virus aus Schritt (iv).
- 40 11. Impfstoff, umfassend ein Coronavirus nach einem der Ansprüche 1 bis 6 und einen pharmazeutisch unbedenklichen Träger.
- 45 12. Impfstoff nach Anspruch 11 zur Verwendung beim Vorbeugen einer Krankheit bei einem Individuum, vorzugsweise wobei es sich bei der Krankheit um infektiöse Bronchitis (IB) handelt, ganz besonders bevorzugt wobei es sich bei der Impfung um eine In-ovo-Impfung handelt.
- 50 13. Impfstoff zur Verwendung nach Anspruch 12, wobei der Impfstoff über Augentropfenverabreichung, intranasale Verabreichung, Trinkwasserverabreichung, Post-hatch-Injektion oder In-ovo-Injektion verabreicht wird.
- 55 14. Verfahren zur Erzeugung eines Impfstoffs nach Anspruch 11, das den Schritt Infizieren einer Wirtszelle mit einem Coronavirus nach einem der Ansprüche 1 bis 6 umfasst.

### Revendications

1. Coronavirus vivant atténué comprenant un gène de réplicase variant qui code pour des poly-protéines comprenant une mutation dans le nsp-14, dans lequel le gène de réplicase variant code pour une protéine comprenant une

## EP 3 172 319 B1

mutation d'acide aminé de Val en Leu au niveau de la position correspondant à la position 393 de la SEQ ID n° : 7.

2. Coronavirus, selon la revendication 1, comprenant en outre une mutation dans un ou plusieurs des nsp-10 correspondant à la SEQ ID n° : 6, nsp-15 correspondant à la SEQ ID n° : 8 et nsp-16 correspondant à la SEQ ID n° : 9.
3. Coronavirus selon la revendication 2, dans lequel le gène de réplicase variant code pour une protéine comprenant une ou plusieurs mutation(s) d'acide(s) aminé(s) choisie(s) parmi : une mutation d'acide aminé de Pro en Leu au niveau de la position correspondant à la position 85 de la SEQ ID n° : 6, une mutation d'acide aminé de Leu en Ile au niveau de la position correspondant à la position 183 de la SEQ ID n° : 8 et une mutation d'acide aminé de Val en Ile au niveau de la position correspondant à la position 209 de la SEQ ID n° : 9.
4. Coronavirus selon l'une quelconque des revendications précédentes, dans lequel le gène de réplicase code pour une protéine comprenant les mutations d'acides aminés : Pro en Leu au niveau de la position correspondant à la position 85 de la SEQ ID n° : 6 ; Val en Leu au niveau de la position correspondant à la position 393 de la SEQ ID n° : 7 ; Leu en Ile au niveau de la position correspondant à la position 183 de la SEQ ID n° : 8 ; et Val en Ile au niveau de la position correspondant à la position 209 de la SEQ ID n° : 9.
5. Coronavirus, selon l'une quelconque des revendications précédentes, qui est un virus de bronchite infectieuse (VBI), de préférence le VBI M41.
6. Coronavirus, selon la revendication 5, qui comprend une protéine S dont au moins une partie provient d'un sérotype de VBI autre que le M41, de préférence dans lequel la sous-unité S1 provient d'un sérotype de VBI autre que le M41 ou dans lequel la protéine S provient d'un sérotype de VBI autre que le M41.
7. Gène de réplicase variant tel que défini dans l'une quelconque des revendications 1 à 4.
8. Protéine codée par un gène de réplicase de coronavirus variant selon la revendication 7.
9. Plasmide comprenant un gène de réplicase selon la revendication 7.
10. Procédé destiné à élaborer le coronavirus selon l'une quelconque des revendications 1 à 6, qui comprend les étapes suivantes :
  - (i) transfecter un plasmide, selon la revendication 9, dans une cellule hôte ;
  - (ii) infecter la cellule hôte avec un virus se recombinant qui comprend le génome d'une souche de coronavirus avec un gène de réplicase, de préférence dans lequel le virus se recombinant est un virus de la vaccine ;
  - (iii) permettre qu'ait lieu une recombinaison homologue entre les séquences du gène de réplicase dans le plasmide et les séquences correspondantes dans le génome du virus se recombinant pour produire un gène de réplicase modifié ; et
  - (iv) faire une sélection en vue d'un virus recombinant qui comprend le gène de réplicase modifié ; en option comprenant en outre l'étape consistant à
  - (v) récupérer un coronavirus recombinant, qui comprend le gène de réplicase modifié, à partir de l'ADN provenant du virus se recombinant de l'étape (iv).
11. Vaccin comprenant un coronavirus, selon l'une quelconque des revendications 1 à 6, et un véhicule acceptable d'un point de vue pharmaceutique.
12. Vaccin, selon la revendication 11, destiné à être utilisé dans la prévention d'une maladie chez un sujet, de préférence la maladie étant une bronchite infectieuse (BI), de manière préférée entre toutes dans lequel la vaccination est une vaccination *in ovo*.
13. Vaccin destiné à être utilisé selon la revendication 12, dans lequel le vaccin est administré via : une administration par gouttes oculaires, une administration intra-nasale, une administration par l'eau de boisson, une injection après l'éclosion ou une injection *in ovo*.
14. Procédé destiné à produire un vaccin, selon la revendication 11, qui comprend l'étape d'infection d'une cellule hôte par un coronavirus selon l'une quelconque des revendications 1 à 6.

FIGURE 1




FIGURE 2





FIGURE 3




FIGURE 4






FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8





FIGURE 9

A



B




FIGURE 10

**Nsp10**

```

      *      20      *      40      *      60      *      80
N41 Nsp10: SRKHETEEVDAVGLSLGCSFAVDPADTYCKYVAASKQPLENCVWMLTVHNGSGFAITSKPSPITPDQDSYGGASVCLYCR
Mod Nsp10: SRKHETEEVDAVGLSLGCSFAVDPADTYCKYVAASKQPLENCVWMLTVHNGSGFAITSKPSPITPDQDSYGGASVCLYCR

      *      100     *      120     *      140
N41 Nsp10: HTAHSGAGNLGRCQFKGSEFVQIPTTEKDPVGFCLRNKVCIVCQWIGYGCOCDSLRQKPSVQ
Mod Nsp10: HTAHSGAGNLGRCQFKGSEFVQIPTTEKDPVGFCLRNKVCIVCQWIGYGCOCDSLRQKPSVQ
    
```

**Nsp14**

```

      *      20      *      40      *      60      *      80
N41 Nsp14: GIGLFRICNKEFGGVHPAYAVTTRALAAAYVWVDELAAIIVWVEAGSEITTRHLLISLLGPFMSVWVEGCHRRFTTRKALR
Mod Nsp14: GIGLFRICNKEFGGVHPAYAVTTRALAAAYVWVDELAAIIVWVEAGSEITTRHLLISLLGPFMSVWVEGCHRRFTTRKALR

      *      100     *      120     *      140     *      160
N41 Nsp14: NVKGVWGFVWEATHACCTNIGTNLDFYWGCFSTGADFWTPEELVDTSIGMNEFVRSKAPPEQDFNHLRALKNSAKPRV
Mod Nsp14: NVKGVWGFVWEATHACCTNIGTNLDFYWGCFSTGADFWTPEELVDTSIGMNEFVRSKAPPEQDFNHLRALKNSAKPRV

      *      180     *      200     *      220     *      240
N41 Nsp14: VFRITWMLAHLNLCWVSDCVVYVTRCHSLELLITLRYFVKIGNDQVCSGGRATTFRSHIQAYACKERCLGDFVYINPLV
Mod Nsp14: VFRITWMLAHLNLCWVSDCVVYVTRCHSLELLITLRYFVKIGNDQVCSGGRATTFRSHIQAYACKERCLGDFVYINPLV

      *      260     *      280     *      300     *      320
N41 Nsp14: DIOGQVYSGMLQFNHBLKSVRCHAHVASADAIMTRCLAINNAFCQIVWMLTYPHIANEDEVNSSCRYIQPMNLNAQV
Mod Nsp14: DIOGQVYSGMLQFNHBLKSVRCHAHVASADAIMTRCLAINNAFCQIVWMLTYPHIANEDEVNSSCRYIQPMNLNAQV

      *      340     *      360     *      380     *      400
N41 Nsp14: ALKVVWVYDHCNPKGKICVBAEDLFRFRYTRNPIVSNVROFEDYDINQHRKTFADGLCMFNSCNVDCYDQSHLRYIDTR
Mod Nsp14: ALKVVWVYDIENPNEIKVRSKILNFRFYDSENPVSNVROFEDYDINQHRKTFADGLCMFNSCNVDCYDQSHLRYIDTR

      *      420     *      440     *      460     *      480
N41 Nsp14: LSYFNLGCGEGSLYVKKHAEHTKFTDRTSFDNLAMDFFTYRSSPCETIQLGVAQDIYSLAKDCITKCNIGGAVCK
Mod Nsp14: LSYFNLGCGEGSLYVKKHAEHTKFTDRTSFDNLAMDFFTYRSSPCETIQLGVAQDIYSLAKDCITKCNIGGAVCK

      *      500     *      520
N41 Nsp14: HQQVADFVTSYBAVYTAGTTFWYINNFNPNLWKSFSALQ
Mod Nsp14: HQQVADFVTSYBAVYTAGTTFWYINNFNPNLWKSFSALQ
    
```

**Nsp15**

```

      *          20          *          40          *          60          *          80
M41 Nsp15: STIDNLIANNMYKGGHYDAGEMPFIIVTGMVFFVIDQGVKAVFFNQTILPESVAFELYAKRNIIRTLQNSRIILKELGVDVI
Mod Nsp15: STIDNLIANNMYKGGHYDAGEMPFIIVTGMVFFVIDQGVKAVFFNQTILPESVAFELYAKRNIIRTLQNSRIILKELGVDVI

      *          100         *          120         *          140         *          160
M41 Nsp15: NGFVIRWYINQITPLAKNTVWVCAITRLEPNGLIVLYDRIYGDYQSPFLAAGNAVLVSTQCYYRYSIVELPSNLLVQNGIPI
Mod Nsp15: NGFVIRWYINQITPLAKNTVWVCAITRLEPNGLIVLYDRIYGDYQSPFLAAGNAVLVSTQCYYRYSIVELPSNLLVQNGIPI

      *          180         *          200         *          220         *          240
M41 Nsp15: KDGNLIVYWRVNGAFVTLPRITLSTQGRSYETFEPSDVEHPLMKSSESFVERVYKRELGLOHILYGEVWKPQLGGLRIV
Mod Nsp15: KDGNLIVYWRVNGAFVTLPRITLSTQGRSYETFEPSDVEHPLMKSSESFVERVYKRELGLOHILYGEVWKPQLGGLRIV

      *          260         *          280         *          300         *          320
M41 Nsp15: IKKCRLLRANKLNKASVINGSDSIVWQWVFLADKGSYKVCVYVWLLADDFLELLRNLKRYGCTNRKSYVTVSIVYRSIL
Mod Nsp15: IKKCRLLRANKLNKASVINGSDSIVWQWVFLADKGSYKVCVYVWLLADDFLELLRNLKRYGCTNRKSYVTVSIVYRSIL

      *
M41 Nsp15: FNWFFDGIHRTVPELG
Mod Nsp15: FNWFFDGIHRTVPELG

```

**Nsp16**

```

      *          20          *          40          *          60          *          80
M41 Nsp16: SRRTCGYRMPLELYKWCNCVMEFCRIIPNNGVGHALPSGIMRNVAVYTLQQLSKTIRKVPHMRWRRHFCAGSDKGVAPGS
Mod Nsp16: SRRTCGYRMPLELYKWCNCVMEFCRIIPNNGVGHALPSGIMRNVAVYTLQQLSKTIRKVPHMRWRRHFCAGSDKGVAPGS

      *          100         *          120         *          140         *          160
M41 Nsp16: TVLQDRLPFGHLLVINDIVDYSDAHVSVLSDCRNRYTEHRKFDLVISSMTDNDPSKRRHDESVIANNQNDVFTYLSSEFLR
Mod Nsp16: TVLQDRLPFGHLLVINDIVDYSDAHVSVLSDCRNRYTEHRKFDLVISSMTDNDPSKRRHDESVIANNQNDVFTYLSSEFLR


      *          180         *          200         *          220         *          240
M41 Nsp16: RRLALGSPAVRWVTESSRHEVLYDIAQDCARRTMECTAYNASSEAFILGVNLLGASPKVYVSKTILHANYIARRNCNYL
Mod Nsp16: RRLALGSPAVRWVTESSRHEVLYDIAQDCARRTMECTAYNASSEAFILGVNLLGASPKVYVSKTILHANYIARRNCNYL

      *          260         *          280         *          300
M41 Nsp16: QTSAYSIPIVWAFEDLKLKATPVVRLKTDQETISWENLIRKCKLLVRIWNGTSTFTNSGPFVETM
Mod Nsp16: QTSAYSIPIVWAFEDLKLKATPVVRLKTDQETISWENLIRKCKLLVRIWNGTSTFTNSGPFVETM


```

FIGURE 11

A)




B)





C)



## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description

- WO 2005049814 A2 [0007]
- WO 2004092360 A [0007]
- WO 2011004146 A [0157] [0190] [0191] [0196]
- WO 2004078203 A [0184]

## Non-patent literature cited in the description

- **MENACHERY, V. D. et al.** *J. Virol.*, 2014, vol. 88 (8), 4251-4264 [0007]
- **DEVEREUX et al.** *Nucleic Acids Research*, 1984, vol. 12, 387 [0094]
- **ATSCHUL et al.** *J. Mol. Biol.*, 1990, 403-410 [0094]
- **LARKIN et al.** Clustal W and Clustal X version 2.0. *Bioinformatics*, 2007, vol. 23, 2947-2948 [0094]
- *FEMS Microbiol Lett*, 1999, vol. 174 (2), 247-50 [0094]
- *FEMS Microbiol Lett*, 1999, vol. 177 (1), 187-8 [0094]
- **AMMAYAPPAN et al.** *Arch Virol*, 2009, vol. 154, 495-499 [0102]
- **CASAIIS et al.** *J. Virol*, 2001, vol. 75, 12359-12369 [0162]
- **CASAIIS et al.** *J. Virol.*, 2003, vol. 77, 9084-9089 [0162]
- **BRITTON et al.** *J. Virological Methods*, 2005, vol. 123, 203-211 [0162]
- **ARMESTO et al.** *Methods in Molecular Biology*, 2008, vol. 454, 255-273 [0162]
- Remington: The Science and Practice of Pharmacy. Lippincott Williams & Wilkins, publ., 2000 [0170]
- The Handbook of Pharmaceutical Excipients. APhA Publications, 2003 [0170]
- **ARMESTO ; CAVANAGH ; BRITTON.** *PLoS ONE*, 2009, vol. 4 (10), e7384 [0191]